<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral paracetamol (acetaminophen) for cancer pain - Wiffen, PJ - 2017 | Cochrane Library</title> <meta content="Oral paracetamol (acetaminophen) for cancer pain - Wiffen, PJ - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012637.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral paracetamol (acetaminophen) for cancer pain - Wiffen, PJ - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012637.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012637.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Oral paracetamol (acetaminophen) for cancer pain" name="citation_title"/> <meta content="Philip J Wiffen" name="citation_author"/> <meta content="Sheena Derry" name="citation_author"/> <meta content="R Andrew Moore" name="citation_author"/> <meta content="andrew.moore@omkltd.org" name="citation_author_email"/> <meta content="Ewan D McNicol" name="citation_author"/> <meta content="Tufts Medical Center" name="citation_author_institution"/> <meta content="Rae Frances Bell" name="citation_author"/> <meta content="Haukeland University Hospital" name="citation_author_institution"/> <meta content="Daniel B Carr" name="citation_author"/> <meta content="Tufts University School of Medicine" name="citation_author_institution"/> <meta content="Mairead McIntyre" name="citation_author"/> <meta content="West Hoe Surgery" name="citation_author_institution"/> <meta content="Bee Wee" name="citation_author"/> <meta content="Churchill Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD012637.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/07/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012637.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012637.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012637.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acetaminophen [*administration &amp; dosage]; Administration, Oral; Analgesics, Non‐Narcotic [*administration &amp; dosage]; Analgesics, Opioid [administration &amp; dosage]; Anti‐Inflammatory Agents, Non‐Steroidal [administration &amp; dosage]; Antidepressive Agents, Tricyclic [administration &amp; dosage]; Antipsychotic Agents [administration &amp; dosage]; Cancer Pain [*drug therapy]; Drug Therapy, Combination; Patient Preference; Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012637.pub2&amp;doi=10.1002/14651858.CD012637.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="KUoIaN9D";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012637\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012637\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012637\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012637\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","pt","ms","hr","fr","th","zh_HANS","fa","zh_HANT"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012637.pub2",title:"Oral paracetamol (acetaminophen) for cancer pain",firstPublishedDate:"Jul 12, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012637.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012637.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012637.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012637.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012637.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012637.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012637.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012637.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012637.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012637.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012637.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012637.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012637.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012637.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11011 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012637.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/full#CD012637-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/full#CD012637-sec-0114"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/full#CD012637-sec-0050"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/full#CD012637-sec-0051"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/full#CD012637-sec-0056"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/full#CD012637-sec-0057"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/full#CD012637-sec-0086"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/full#CD012637-sec-0108"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012637.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/appendices#CD012637-sec-0126"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012637.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral paracetamol (acetaminophen) for cancer pain</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/information#CD012637-cr-0002">Philip J Wiffen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/information#CD012637-cr-0003">Sheena Derry</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/information#CD012637-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>R Andrew Moore</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/information#CD012637-cr-0005">Ewan D McNicol</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/information#CD012637-cr-0006">Rae Frances Bell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/information#CD012637-cr-0007">Daniel B Carr</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/information#CD012637-cr-0008">Mairead McIntyre</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012637.pub2/information#CD012637-cr-0009">Bee Wee</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012637.pub2/information/en#CD012637-sec-0136">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 July 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012637.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012637.pub2">https://doi.org/10.1002/14651858.CD012637.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012637-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012637-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012637-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012637-abs-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012637-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012637-abs-0002">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD012637-abs-0013">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012637-abs-0015">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012637-abs-0001" lang="en"> <section id="CD012637-sec-0001"> <h3 class="title" id="CD012637-sec-0001">Background</h3> <p>Pain is a common symptom with cancer, and 30% to 50% of all people with cancer will experience moderate to severe pain that can have a major negative impact on their quality of life. Non‐opioid drugs are commonly used to treat mild to moderate cancer pain, and are recommended for this purpose in the WHO cancer pain treatment ladder, either alone or in combination with opioids. </p> <p>A previous Cochrane review that examined the evidence for nonsteroidal anti‐inflammatory drugs (NSAIDs) or paracetamol, alone or combined with opioids, for cancer pain was withdrawn in 2015 because it was out of date; the date of the last search was 2005. This review, and another on NSAIDs, updates the evidence. </p> </section> <section id="CD012637-sec-0002"> <h3 class="title" id="CD012637-sec-0002">Objectives</h3> <p>To assess the efficacy of oral paracetamol (acetaminophen) for cancer pain in adults and children, and the adverse events reported during its use in clinical trials. </p> </section> <section id="CD012637-sec-0003"> <h3 class="title" id="CD012637-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase from inception to March 2017, together with reference lists of retrieved papers and reviews, and two online study registries. </p> </section> <section id="CD012637-sec-0004"> <h3 class="title" id="CD012637-sec-0004">Selection criteria</h3> <p>We included randomised, double‐blind, studies of five days' duration or longer, comparing paracetamol alone with placebo, or paracetamol in combination with an opioid compared with the same dose of the opioid alone, for cancer pain of any intensity. Single‐blind and open studies were also eligible for inclusion. The minimum study size was 25 participants per treatment arm at the initial randomisation. </p> </section> <section id="CD012637-sec-0005"> <h3 class="title" id="CD012637-sec-0005">Data collection and analysis</h3> <p>Two review authors independently searched for studies, extracted efficacy and adverse event data, and examined issues of study quality and potential bias. We did not carry out any pooled analyses. We assessed the quality of the evidence using GRADE and created a 'Summary of findings' table. </p> </section> <section id="CD012637-sec-0006"> <h3 class="title" id="CD012637-sec-0006">Main results</h3> <p>Three studies in adults satisfied the inclusion criteria, lasting up to one week; 122 participants were randomised initially, and 95 completed treatment. We found no studies in children. One study was parallel‐group, and two had a cross‐over design. All used paracetamol as an add‐on to established treatment with strong opioids (median daily morphine equivalent doses of 60 mg, 70 mg, and 225 mg, with some participants taking several hundred mg of oral morphine equivalents daily). Other non‐paracetamol medication included non‐steroidal anti‐inflammatory drugs (NSAIDs), tricyclic antidepressants, or neuroleptics. All studies were at high risk of bias for incomplete outcome data and small size; none was unequivocally at low risk of bias. </p> <p>None of the studies reported any of our primary outcomes: participants with pain reduction of at least 50%, and at least 30%, from baseline; participants with pain no worse than mild at the end of the treatment period; participants with Patient Global Impression of Change (PGIC) of much improved or very much improved (or equivalent wording). What pain reports there were indicated no difference between paracetamol and placebo when added to another treatment. There was no convincing evidence of paracetamol being different from placebo with regards to quality of life, use of rescue medication, or participant satisfaction or preference. Measures of harm (serious adverse events, other adverse events, and withdrawal due to lack of efficacy) were inconsistently reported and provided no clear evidence of difference. </p> <p>Our GRADE assessment of evidence quality was very low for all outcomes, because studies were at high risk of bias from several sources. </p> </section> <section id="CD012637-sec-0007"> <h3 class="title" id="CD012637-sec-0007">Authors' conclusions</h3> <p>There is no high‐quality evidence to support or refute the use of paracetamol alone or in combination with opioids for the first two steps of the three‐step WHO cancer pain ladder. It is not clear whether any additional analgesic benefit of paracetamol could be detected in the available studies, in view of the doses of opioids used. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012637-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012637-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012637-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012637-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012637-abs-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012637-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012637-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012637-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012637-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012637-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD012637-abs-0014">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012637-abs-0016">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012637-abs-0019">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012637-abs-0005" lang="en"> <h3>Paracetamol for cancer pain</h3> <p><b>Bottom line</b> </p> <p>There is no evidence to show that paracetamol is useful in treating people with cancer pain, either alone or combined with a morphine‐like drug. Nor is there evidence to disprove that it is useful. There are no good studies evaluating paracetamol for management of cancer pain. </p> <p><b>Background</b> </p> <p>One person in two or three who gets cancer will suffer from pain that becomes moderate or severe in intensity. The pain tends to get worse as the cancer progresses. In 1986, the World Health Organization recommended taking morphine‐like drugs (opioids) for moderate to severe pain from cancer, and non‐opioid drugs like paracetamol, alone for mild to moderate pain, or alongside opioids in people with moderate to severe pain. </p> <p><b>Study characteristics</b> </p> <p>In this review we set out to examine all the evidence on how well paracetamol (alone or with morphine‐like drugs) worked in adults and children with cancer pain. We also wanted to know how many people had side effects, and how severe those side effects were, for example, whether they caused people to stop taking their medicines. </p> <p>In March 2017, we found three studies with 122 participants. All compared paracetamol plus opioid with the same dose of opioid alone. The studies were small, and were of poor quality. They used different study designs and different ways of showing their pain results. Outcomes of importance to people with cancer pain were not reported. </p> <p><b>Key findings</b> </p> <p>We found no evidence that taking paracetamol alone made any difference to the level of pain experienced. We found no evidence that taking paracetamol together with a morphine‐like drug was better than the morphine‐like drug alone. Paracetamol did not appear to improve quality of life. No conclusions could be reached about side effects. The amount of information and the differences in how studies were reported meant that no conclusions could be made. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence was very low. Very low‐quality evidence means that we are very uncertain about the impact of paracetamol for treating cancer pain. We do not know whether using paracetamol alone, or in combination with an opioid such as codeine or morphine, is worthwhile. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012637-sec-0114" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012637-sec-0114"></div> <h3 class="title" id="CD012637-sec-0115">Implications for practice</h3> <section id="CD012637-sec-0115"> <section id="CD012637-sec-0116"> <h5 class="title">For people with cancer pain</h5> <p>The amount and quality of evidence around the use of paracetamol for treating cancer pain is low. The small amount of evidence we have does not indicate that it has any pain‐relieving effects or makes any improvement to quality of life. No judgement can be made about adverse events or withdrawals. </p> </section> <section id="CD012637-sec-0117"> <h5 class="title">For clinicians</h5> <p>There is no evidence for paracetamol alone. The evidence we have is from add‐on studies with oral morphine doses of 60 mg daily or above, when any additional analgesic effect of oral paracetamol would be difficult to detect. It may be possible to reduce the drug burden for people with cancer pain taking such large amounts of oral morphine equivalents, but we have no evidence that this is the case. </p> <p>The amount and quality of evidence around the use of paracetamol for treating cancer pain is low. There is no evidence supporting or refuting the use of paracetamol on the first and second steps of the WHO ladder. The small amount of evidence we have for the use of paracetamol combined with opioids does not indicate that it has any additional pain‐relieving effects or makes any improvement to quality of life. No judgement can be made about adverse events or withdrawals. </p> </section> <section id="CD012637-sec-0118"> <h5 class="title">For policy makers</h5> <p>The amount and quality of evidence around the use of paracetamol for treating cancer pain is low. There is no evidence supporting or refuting the use of paracetamol on the first step of the WHO ladder. The small amount of evidence we have for the use of paracetamol combined with strong opioids does not indicate that it has any additional pain‐relieving effects or makes any improvement to quality of life. No judgement can be made about adverse events or withdrawals. </p> </section> <section id="CD012637-sec-0119"> <h5 class="title">For funders</h5> <p>The amount and quality of evidence around the use of paracetamol for treating cancer pain is low. There is no evidence supporting or refuting the use of paracetamol on the first step of the WHO ladder. The small amount of evidence we have for the use of paracetamol combined with strong opioids does not indicate that it has any additional pain‐relieving effects or makes any improvement to quality of life. No judgement can be made about adverse events or withdrawals. </p> </section> </section> <h3 class="title" id="CD012637-sec-0120">Implications for research</h3> <section id="CD012637-sec-0120"> <section id="CD012637-sec-0121"> <h5 class="title">General</h5> <p>This review on paracetamol for cancer pain reveals major problems with the evidence available. The WHO pain ladder is now over 30 years old, and remains probably the most‐used and best‐understood pain guidance worldwide. Despite its obvious importance there are few studies that clearly demonstrate how best to perform a study on the lower two steps, which relate to the treatment of mild and moderate pain with non‐opoid drugs like paracetamol, alone or in combination with weak opioids. As best we know there are no ongoing studies examining the use of paracetamol alone for mild to moderate pain for the first step of the WHO ladder. We know of one ongoing study examining paracetamol plus opioid for the second or third step of the ladder. In this study, participants with moderate to severe pain (3/10 to 9/10) who are taking daily opioid plus 4 x 1000 mg paracetamol are randomised to continued treatment with the combination or the opioid alone. </p> </section> <section id="CD012637-sec-0122"> <h5 class="title">Design</h5> <p>Several methodological issues stand out.</p> <p>The first is the use of outcomes of value to people with cancer pain. Existing trials are designed more for purposes of registration and marketing than informing and improving clinical practice, often because the outcomes chosen are average pain scores, or statistical differences, and rarely how many individuals achieve satisfactory pain relief. In the situation where initial pain is mild or moderate, some consideration needs to be given to what constitutes a satisfactory outcome. The situation is somewhat different to that of strong opioids in cancer pain that are used for moderate to severe pain. </p> <p>The second is the time taken to achieve good pain relief. We have no information about what constitutes a reasonable time to achieve a satisfactory result. Initially, this may best be approached with a Delphi methodology. </p> <p>The third is design. Studies with cross‐over design often have significant attrition. Parallel group designs may be preferable, and while this is a matter of debate (<a href="./references#CD012637-bbs2-0020" title="BellRF , WisløffT , EcclestonC , KalsoE . Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review. British Journal of Cancer2006;94(11):1559‐67. [DOI: 10.1038/sj.bjc.6603162] ">Bell 2006</a>), considerable thinking has already gone into study design. </p> <p>The fourth is size. The studies were small, and, combined with cross‐over design and consequent attrition, ended up reporting on very few participants. Much larger studies of several hundred participants or more are needed. </p> <p>The fifth is the dose of opioid allowable in add‐on studies to test the analgesic efficacy or effectiveness of oral paracetamol. In the circumstance of high oral opioid doses, additional benefit is unlikely to be measurable, and some upper limit of opioid dose may be needed. </p> <p>The sixth is that in the current era of precision medicine investigator may have an opportunity to conduct clinical trials involving specific aetiologies of cancer pain, or accrue sufficient numbers of participants to conduct well‐powered subgroup analyses. </p> <p>There are some other design issues that might be addressed. Most important might be a clear decision concerning the gold‐standard treatment comparator. Placebo‐controlled studies in cancer pain are unlikely to be ethically feasible (<a href="./references#CD012637-bbs2-0020" title="BellRF , WisløffT , EcclestonC , KalsoE . Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review. British Journal of Cancer2006;94(11):1559‐67. [DOI: 10.1038/sj.bjc.6603162] ">Bell 2006</a>). It may be that low‐dose oral morphine is a suitable comparator, as a suggested alternative treatment for mild to moderate pain (<a href="./references#CD012637-bbs2-0105" title="TwycrossR , WilcockA , HowardP . Palliative Care Formulary. Nottingham: Palliativedrugs.com Ltd, 2014. ">Twycross 2014</a>). </p> </section> <section id="CD012637-sec-0123"> <h5 class="title">Measurement (endpoints)</h5> <p>Trials need to consider the additional endpoints of no worse than mild pain and the impact of morphine on symptoms that raise serious concerns such as consciousness, appetite, and thirst, outcomes identified previously as important (<a href="./references#CD012637-bbs2-0110" title="WiffenPJ , DerryS , MooreRA . Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database of Systematic Reviews2014, Issue 5. [DOI: 10.1002/14651858.CD011056.pub2] ">Wiffen 2014</a>). The choice of measures to be used in cancer pain studies is not necessarily straightforward. </p> </section> <section id="CD012637-sec-0124"> <h5 class="title">Other</h5> <p>Prospective randomised trials are the obvious design of choice, but other pragmatic designs may be worth considering. Studies could incorporate initial randomisation but a pragmatic design in order to provide immediately‐relevant information on effectiveness and costs. Such designs in pain conditions have been published (<a href="./references#CD012637-bbs2-0078" title="MooreRA , DerryS , McQuayHJ , StraubeS , AldingtonD , WiffenP , et al. Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. Pain2010;149(2):173‐6. [DOI: 10.1016/j.pain.2009.08.007] ">Moore 2010b</a>). </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012637-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012637-sec-0050"></div> <div class="table" id="CD012637-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Paracetamol plus opioid compared with the same dose of opioid alone for cancer pain</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cancer pain </p> <p><b>Settings:</b> inpatient or outpatient </p> <p><b>Intervention:</b> paracetamol plus opioid </p> <p><b>Comparison:</b> same dose of opioid alone </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> opioid + paracetamol</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> opioid alone</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>RR<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of studies, participants</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with at least 30% or at least 50% reduction in pain</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality because no or inadequate data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PGIC much or very much improved</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality because no or inadequate data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean pain intensity at end of study</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No difference between treatment groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies, 93 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality because no or inadequate data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain no worse than mild at one or two weeks (or equivalent)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality because no or inadequate data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean quality of life or "well‐being"</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No difference between treatment groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies, 93 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality because no or inadequate data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant preference</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Better: 15/52</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Better: 9/52</p> <p>(No different: 28/52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies, 52 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality because no or inadequate data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No difference between groups for specific opioid‐related adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies, 80 participants (maximum)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality because no or inadequate data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>None specifically reported. 1 death due to underlying disease ‐ treatment unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies, 93 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality because no or inadequate data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Descriptors for levels of evidence (<a href="./references#CD012637-bbs2-0044" title="EffectivePractice , Organisation of Care(EPOC) . 23. Worksheets for preparing a Summary of Findings using GRADE. Resources for review authors. epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 30 November 2016). ">EPOC 2015</a>):<br/> <b>High quality:</b> This research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is low.<br/> <b>Moderate quality:</b> This research provides a good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is moderate.<br/> <b>Low quality:</b> This research provides some indication of the likely effect. However, the likelihood that it will be substantially different<sup>†</sup> is high.<br/> <b>Very low quality:</b> This research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is very high. </p> <p><sup>†</sup> Substantially different: a large enough difference that it might affect a decision. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012637-sec-0051" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012637-sec-0051"></div> <p>A previous Cochrane review that examined the evidence for nonsteroidal anti‐inflammatory drugs (NSAIDs) or paracetamol, alone or combined with opioids, for cancer pain was withdrawn in 2015 because it was out of date (<a href="./references#CD012637-bbs2-0116" title="McNicolED , StrasselsS , GoudasL , LauJ , CarrDB . NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD005180.pub2] ">McNicol 2015</a>); the date of the last search was 2005. </p> <p>This is one of three reviews on the efficacy and safety of oral non‐opioid medicines to treat cancer pain, in this case focusing on paracetamol in adults and children. Another review will examine oral NSAIDs in adults (<a href="./references#CD012637-bbs2-0039" title="DerryS , WiffenPJ , MooreRA , McNicolED , BellRF , CarrDB , et al. Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD012638] ">Derry 2017</a>). A separate review will examine the efficacy of NSAIDs for cancer pain in children (<a href="./references#CD012637-bbs2-0028" title="CooperTE , HeathcoteLC , AndersonB , GrégoireMC , LjungmanG , EcclestonC . Non‐steroidal anti‐inflammatory drugs (NSAIDs) for cancer‐related pain in children and adolescents. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD012563] ">Cooper 2017</a>). </p> <section id="CD012637-sec-0052"> <h3 class="title" id="CD012637-sec-0052">Description of the condition</h3> <p>Cancer is estimated to cause over eight million deaths per annum ‐ approximately 13% of deaths worldwide (<a href="./references#CD012637-bbs2-0063" title="International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (accessed 21 November 2016). ">IARC 2012</a>). Globally, 32 million people are living with cancer, and detailed information for individual countries is available on the WHO website for the International Agency for Research on Cancer (<a href="http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx" target="_blank">http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx</a>). In the UK alone in 2014, there were around 350,000 new cases of cancer annually, with around 50% of people surviving for 10 years or more after diagnosis (<a href="./references#CD012637-bbs2-0025" title="Cancer statistics for the UK. www.cancerresearchuk.org/health‐professional/cancer‐statistics (accessed 21 November 2016). ">Cancer Research UK 2016</a>). </p> <p>Cancer pain is perhaps one of the most feared symptoms associated with the disease. Pain may be the first symptom to cause someone to seek medical advice that leads to a diagnosis of cancer, and 30% to 50% of all people with cancer will experience moderate to severe pain (<a href="./references#CD012637-bbs2-0091" title="PortenoyRK , LesageP . Management of cancer pain. Lancet1999;353(9165):1695‐700. [DOI: 10.1016/S0140‐6736(99)01310‐0] ">Portenoy 1999</a>). Pain can occur at any time as the disease progresses, but the frequency and intensity of pain tends to increase as the cancer advances (<a href="./references#CD012637-bbs2-0091" title="PortenoyRK , LesageP . Management of cancer pain. Lancet1999;353(9165):1695‐700. [DOI: 10.1016/S0140‐6736(99)01310‐0] ">Portenoy 1999</a>; <a href="./references#CD012637-bbs2-0107" title="Van denBeuken‐van EverdingenMH , HochstenbachLM , JoostenEA , Tjan‐HeijnenVC , JanssenDJ . Update on prevalence of pain in patients with cancer: systematic review and meta‐analysis. Journal of Pain and Symptom Management2016;51:1070‐90. [DOI: 10.1016/j.jpainsymman.2015.12.340] ">Van den Beuken‐van Everdingen 2016</a>). For people with advanced cancer, some 75% to 90% will experience pain having a major impact on daily living (<a href="./references#CD012637-bbs2-0112" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a>). Pain had a significant negative correlation with quality of life in people with cancer in China, Japan, and Palestine, for example (<a href="./references#CD012637-bbs2-0036" title="DengD , FuL , ZhaoYX , WuX , ZhangG , LiangC , et al. The relationship between cancer pain and quality of life in patients newly admitted to Wuhan Hospice Center of China. American Journal of Hospital Palliative Care2012;29(1):53‐9. [DOI: 10.1177/1049909111418636] ">Deng 2012</a>; <a href="./references#CD012637-bbs2-0040" title="DreidiMM , Hamdan‐MansourAM . Pain, sleep disturbance, and quality of life among Palestinian patients diagnosed with cancer. Journal of Cancer Education2016;31(4):796‐803. [DOI: 10.1007/s13187‐015‐0946‐5] ">Dreidi 2016</a>; <a href="./references#CD012637-bbs2-0074" title="MikanF , WadaM , YamadaM , TakahashiA , OnishiH , IshidaM , et al. The association between pain and quality of life for patients with cancer in an outpatient clinic, an inpatient oncology ward, and inpatient palliative care units. American Journal of Hospital Palliative Care2016;33(8):782‐90. [DOI: 10.1177/1049909116630266] ">Mikan 2016</a>). A recent systematic review has shown that approximately 40% of patients suffered pain after curative treatment, 55% during cancer treatment and 66% in advanced disease. Pain related to cancer is frequently described as distressing or intolerable by more than one‐third of patients (<a href="./references#CD012637-bbs2-0022" title="BreivikH , ChernyN , CollettB , DeConnoF , FilbetM , FoubertAJ , et al. Cancer‐related pain: a pan‐European survey of prevalence, treatment, and patient attitudes. Annals of Oncology2009;20(8):1420‐33. [DOI: 10.1093/annonc/mdp001] ">Breivik 2009</a>; <a href="./references#CD012637-bbs2-0107" title="Van denBeuken‐van EverdingenMH , HochstenbachLM , JoostenEA , Tjan‐HeijnenVC , JanssenDJ . Update on prevalence of pain in patients with cancer: systematic review and meta‐analysis. Journal of Pain and Symptom Management2016;51:1070‐90. [DOI: 10.1016/j.jpainsymman.2015.12.340] ">Van den Beuken‐van Everdingen 2016</a>). </p> <p>Cancer pain can be the result of the cancer itself, interventions to treat the cancer, and sometimes other underlying pains. Cancer‐related pain is a mosaic of different types of pain generated through different mechanisms. The biology of pain from bone metastasis may well differ from pain due to obstruction of a viscus (internal organ) or invasion of soft tissue, resulting in differences in responsiveness to analgesics that act via different mechanisms. Prevalence of pain is also linked to cancer type, with head and neck cancer showing the highest prevalence. Age also has an impact, with younger patients experiencing more pain (<a href="./references#CD012637-bbs2-0093" title="PrommerEE . Pharmacological management of cancer‐related pain. Cancer Control2015;22(4):412‐25. [PUBMED: 26678968] ">Prommer 2015</a>). For this review, we will not consider postsurgical pain or specific neuropathic pain conditions. </p> <p>The current World Health Organization (WHO) cancer pain ladder for adults recommends the use of non‐opioid analgesics, including paracetamol, as the first step on the ladder, with or without an adjuvant (<a href="./references#CD012637-bbs2-0109" title="Anonymous . WHO analgesic ladder. www.who.int/cancer/palliative/painladder/en/ (accessed 10 April 2017). ">WHO 2017</a>). Non‐opioid analgesics are also to be used on the second and third steps, together with weak or strong opioids. The current National Institute for Health and Care Excellence (NICE) in the UK advises that non‐opioid analgesics alone be used for treating mild pain (0 to 3 on a 0 to 10 pain scale), together with a weak opioid such as codeine or tramadol for mild to moderate pain (3 to 6), and with a strong opioid such as morphine for severe pain (6 to 10) (<a href="./references#CD012637-bbs2-0086" title="National Institute for Health and Care Excellence. Palliative cancer care ‐ pain. cks.nice.org.uk/palliative‐cancer‐care‐pain (accessed 02 February 2017). ">NICE 2016</a>). Some authorities have suggested that the second step on the ladder could be removed, and replaced with low doses of strong opioids such as morphine (<a href="./references#CD012637-bbs2-0105" title="TwycrossR , WilcockA , HowardP . Palliative Care Formulary. Nottingham: Palliativedrugs.com Ltd, 2014. ">Twycross 2014</a>). </p> <p>Children with cancer consider pain as the most prevalent symptom, usually resulting from treatment side effects or painful procedures (<a href="./references#CD012637-bbs2-0106" title="TwycrossA , ParkerR , WilliamsA , GibsonF . Cancer‐related pain and pain management: sources, prevalence, and the experiences of children and parents. Journal of Paediatric Oncology Nursing2015;32(6):369‐84. [DOI: 10.1177/1043454214563751] ">Twycross 2015</a>). The amount and quality of research on pharmacological treatments for children tends to be poor (<a href="./references#CD012637-bbs2-0073" title="MercadanteS , GiarratanoA . Pharmacological management of cancer pain in children. Clinical Reviews in Oncology and Hematology2014;91(1):93‐7. [DOI: 10.1016/j.critrevonc.2014.01.005] ">Mercadante 2014</a>). </p> </section> <section id="CD012637-sec-0053"> <h3 class="title" id="CD012637-sec-0053">Description of the intervention</h3> <p>Paracetamol (acetaminophen) is available in a very large number of formulations and products with different names, including Panadol and Tylenol. Paracetamol plus codeine often comes with the generic name co‐codamol, and paracetamol plus dihydrocodeine as co‐dydramol. A listing of brand names by country is available but the list is too long to be given here (<a href="./references#CD012637-bbs2-0041" title="Anonymous . Paracetamol. www.drugs.com/international/paracetamol.html (accessed 10 May 2016). ">Drugs.com 2016</a>). Worldwide paracetamol use is measured in thousands of tonnes annually, and questions have been asked about the benefits and risk of such extensive use (<a href="./references#CD012637-bbs2-0083" title="MooreRA , MooreN . Paracetamol and pain: the kiloton problem. European Journal of Hospital Pharmacy2016;23(4):187‐8. [DOI: 10.1136/ejhpharm‐2016‐000952] ">Moore 2016</a>). </p> <p>Paracetamol was first identified as the active metabolite of two older antipyretic drugs, acetanilide and phenacetin, in the late nineteenth century (<a href="./references#CD012637-bbs2-0015" title="AxelrodJ . Journey of a late blooming biochemical neuroscientist. Journal of Biology and Chemistry2003;278(1):1‐13. ">Axelrod 2003</a>). Since then, it has become one of the most popular antipyretic and analgesic drugs worldwide, and is often also used in combination with other drugs. It became available in the UK on prescription in 1956, and without prescription (over‐the‐counter) in 1963 (<a href="./references#CD012637-bbs2-0090" title="PharmWeb . Paracetamol Information Centre. www2.pharmweb.net/pwmirror/pwy/paracetamol/pharmwebpic.html (accessed 18 January 2016). ">PIC 2015</a>). Nonprescription medications are less expensive, more accessible, and have favourable safety profiles relative to many prescription treatments. There have been calls for the position of paracetamol as a widely‐available analgesic to be re‐evaluated, based on an assessment of evidence over the past 130 years (<a href="./references#CD012637-bbs2-0024" title="BruneK , RennerB , TiegsG . Acetaminophen/paracetamol: a history of errors, failures and false decisions. European Journal of Pain2015;19(7):953‐65. [10.1002/ejp.621] ">Brune 2015</a>). </p> <p>Despite a low incidence of adverse effects, paracetamol has a recognised potential for hepatotoxicity and is thought to be responsible for approximately half of all cases of liver failure in the UK (<a href="./references#CD012637-bbs2-0059" title="HawtonK , TownsendE , DeeksJ , ApplebyL , GunnellD , BennewithO , et al. Effects of legislation restricting pack sizes of paracetamol and salicylate on self poisoning in the United Kingdom: before and after study. BMJ2001;322(7296):1203‐7. [DOI: 10.1136/bmj.322.7296.1203] ">Hawton 2001</a>), and about 40% in the USA (<a href="./references#CD012637-bbs2-0087" title="NorrisW , ParedesAH , LewisJH . Drug‐induced liver injury in 2007. Current Opinion in Gastroenterology2008;24(3):287‐97. [DOI: 10.1097/MOG.0b013e3282f9764b] ">Norris 2008</a>). One study, evaluating all cases of acute liver failure leading to registration for transplantation (ALFT) across seven European countries for a three‐year period, showed that paracetamol overdose was responsible for one‐sixth of cases of ALFT, though this varied considerably between each country (<a href="./references#CD012637-bbs2-0052" title="GulmezSE , LarreyD , PageauxGP , BernuauJ , BissoliF , HorsmansY , et al. Liver transplant associated with paracetamol overdose: results from the seven‐country SALT study. British Journal of Clinical Pharmacology2015;80(3):599‐606. [DOI: 10.1111/bcp.12635] ">Gulmez 2015</a>). Acute paracetamol hepatotoxicity at therapeutic doses has been judged to be extremely unlikely, despite reports of so‐called 'therapeutic misadventure' (<a href="./references#CD012637-bbs2-0092" title="PrescottLF . Therapeutic misadventure with paracetamol: fact or fiction?. American Journal of Therapeutics2000;7(2):99‐114. [PUBMED: 11319578] ">Prescott 2000</a>). However, it has been observed that non‐overdose ALFT is more likely to follow therapeutic‐dose paracetamol exposure than similar NSAID exposure (<a href="./references#CD012637-bbs2-0051" title="GulmezSE , LarreyD , PageauxGP , LignotS , LassalleR , JovéJ , et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case‐population SALT study. Drug Safety2013;36(2):135‐44. [DOI: 10.1007/s40264‐012‐0013‐7] ">Gulmez 2013</a>). Legislative changes have been introduced in the UK to restrict pack sizes and the maximum number of tablets permitted in nonprescription sales (<a href="./references#CD012637-bbs2-0029" title="Committee on Safety of Medicines. Medicines Control Agency. Paracetamol and aspirin. Current Problems in Pharmacovigilance1997;23:9. ">CSM 1997</a>), on the basis of evidence that poisoning is lower in countries that restrict availability (<a href="./references#CD012637-bbs2-0053" title="GunnellD , HawtonK , GarnierV , BismuthC , FaggJ . Use of paracetamol for suicide and non‐fatal poisoning in the UK and France: are restrictions on availability justified?. Journal of Epidemiology and Community Health1997;51(2):175‐9. [PUBMED: 9196648] ">Gunnell 1997</a>; <a href="./references#CD012637-bbs2-0059" title="HawtonK , TownsendE , DeeksJ , ApplebyL , GunnellD , BennewithO , et al. Effects of legislation restricting pack sizes of paracetamol and salicylate on self poisoning in the United Kingdom: before and after study. BMJ2001;322(7296):1203‐7. [DOI: 10.1136/bmj.322.7296.1203] ">Hawton 2001</a>). The contribution of these changes, which were inconvenient and costly (particularly to people with chronic pain), to any observed reductions in incidence of liver failure or death, remains uncertain (<a href="./references#CD012637-bbs2-0018" title="BatemanDN , CarrollR , PettieJ , YamamotoT , ElaminME , PeartL , et al. Effect of the UK's revised paracetamol poisoning management guidelines on admissions, adverse reactions, and costs of treatment. British Journal of Clinical Pharmacology2014;78(3):610‐8. [DOI: 10.1111/bcp.12362] ">Bateman 2014a</a>; <a href="./references#CD012637-bbs2-0019" title="BatemanDN . Pack size and paracetamol overdose: 16 years later. Clinical Toxicology2014;52:821‐3. [DOI: 10.3109/15563650.2014.952432] ">Bateman 2014b</a>; <a href="./references#CD012637-bbs2-0058" title="HawkinsLC , EdwardsJN , DarganPI . Impact of restricting paracetamol pack sizes on paracetamol poisoning in the United Kingdom: a review of the literature. Drug Safety2007;30(6):465‐79. [PUBMED: 17536874] ">Hawkins 2007</a>; <a href="./references#CD012637-bbs2-0060" title="HawtonK , BergenH , SimkinS , DoddS , PocockP , BernalW , et al. Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: interrupted time series analyses. BMJ2013;346:f403. [DOI: 10.1136/bmj.f403] ">Hawton 2013</a>). Changes have also been made in the USA, and professionals have been advised not to dispense prescription combination drugs with more than 325 mg paracetamol (<a href="./references#CD012637-bbs2-0046" title="HertzS . Review of Acetaminophen for the Withdrawn or Removed List. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pharmacycompoundingadvisorycommittee/ucm449535.pdf May 13 2015 (Accessed May 30 2017):44 et seq. ">FDA 2015</a>). </p> <p>There is a substantial public health impact of paracetamol toxicity. In the USA, incidence proportions peaked at age two years and ages 16 to 18 years (<a href="./references#CD012637-bbs2-0014" title="AltyarA , KordiL , SkrepnekG . Clinical and economic characteristics of emergency department visits due to acetaminophen toxicity in the USA. BMJ Open2015;5(9):e007368. [DOI: 10.1136/bmjopen‐2014‐007368] ">Altyar 2015</a>). There have been concerns over the safety of paracetamol in people with compromised hepatic function (people with severe alcoholism, cirrhosis, or hepatitis), but these have not been substantiated (<a href="./references#CD012637-bbs2-0032" title="DartRC , KuffnerEK , RumackBH . Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review. American Journal of Medicine2000;7(2):123‐34. [PUBMED: 11319580] ">Dart 2000</a>; <a href="./references#CD012637-bbs2-0090" title="PharmWeb . Paracetamol Information Centre. www2.pharmweb.net/pwmirror/pwy/paracetamol/pharmwebpic.html (accessed 18 January 2016). ">PIC 2015</a>). </p> <p>The use of paracetamol during pregnancy has been questioned following reports that it is linked to behavioural problems and hyperkinetic disorders in children whose mothers took it during pregnancy (<a href="./references#CD012637-bbs2-0066" title="LiewZ , RitzB , RebordosaC , LeePC , OlsenJ . Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disorders. JAMA Pediatrics2014;168(4):313‐20. [DOI: 10.1001/jamapediatrics.2013.4914] ">Liew 2014</a>), and suggestions that it can interfere with sex hormones (<a href="./references#CD012637-bbs2-0068" title="Mazaud‐GuittotS , Nicolas NicolazC , Desdoits‐LethimonierC , CoiffecI , Ben MaamarM , BalaguerP , et al. Paracetamol, aspirin, and indomethacin induce endocrine disturbances in the human fetal testis capable of interfering with testicular descent. Journal of Clinical Endocrinology and Metabolism2013;98(11):1757‐67. [DOI: 10.1210/jc.2013‐2531] ">Mazaud‐Guittot 2013</a>). </p> <p>In an analysis of single‐dose studies in migraine, there was no evidence that adverse events were more common with paracetamol 1000 mg than with placebo, and no serious adverse events occurred with paracetamol alone (<a href="./references#CD012637-bbs2-0037" title="DerryS , MooreRA . Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD008040.pub3] ">Derry 2013</a>). </p> <p>Oral paracetamol has long been used as a first‐line analgesic for a variety of acute and chronic conditions. It has modest efficacy in acute pain and migraine (<a href="./references#CD012637-bbs2-0037" title="DerryS , MooreRA . Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD008040.pub3] ">Derry 2013</a>; <a href="./references#CD012637-bbs2-0103" title="TomsL , McQuayHJ , DerryS , MooreRA . Single dose oral paracetamol (acetaminophen) for postoperative pain in adults. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD004602.pub2] ">Toms 2008</a>), but some randomised trials, systematic reviews, and meta‐analyses have suggested that there is no good evidence for a clinically relevant benefit of paracetamol (as monotherapy) in many chronic pain conditions, such as osteoarthritis and back pain (<a href="./references#CD012637-bbs2-0067" title="MachadoGC , MaherCG , FerreiraPH , PinheiroMB , LinCW , DayRO , et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta‐analysis of randomised placebo controlled trials. BMJ2015;350:h1225. [DOI: 10.1136/bmj.h1225] ">Machado 2015</a>; <a href="./references#CD012637-bbs2-0082" title="MooreRA , DerryS , WiffenPJ , StraubeS , AldingtonDJ . Overview review: comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions. European Journal of Pain2014;19(9):1213‐23. [DOI: 10.1002/ejp.649] ">Moore 2014a</a>; <a href="./references#CD012637-bbs2-0114" title="WilliamsCM , MaherCG , LatimerJ , McLachlanAJ , HancockMJ , DayRO , et al. Efficacy of paracetamol for acute low‐back pain: a double‐blind, randomised controlled trial. Lancet2014;384(9954):1586‐96. [DOI: 10.1016/S0140‐6736(14)60805‐9] ">Williams 2014</a>). There are few or no data for a range of other common painful conditions, including dysmenorrhoea and chronic neck pain. Moreover, accumulating evidence from observational studies indicates a considerable degree of paracetamol toxicity, especially at the upper end of standard analgesic doses (<a href="./references#CD012637-bbs2-0096" title="RobertsE , Delgado NunesV , BucknerS , LatchemS , ConstantiM , MillerP , et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Annals of the Rheumatic Diseases2016;75(3):552‐9. [DOI: 10.1136/annrheumdis‐2014‐206914] ">Roberts 2016</a>). </p> </section> <section id="CD012637-sec-0054"> <h3 class="title" id="CD012637-sec-0054">How the intervention might work</h3> <p>The lack of significant anti‐inflammatory activity of paracetamol implies a mode of action distinct from that of NSAIDs; yet, despite years of use and research, the mechanisms of action of paracetamol are not fully understood. NSAIDs act by inhibiting the activity of cyclo‐oxygenase (COX), now recognised to consist of two isoforms (COX‐1 and COX‐2), which catalyse the production of prostaglandins responsible for pain and inflammation. Paracetamol has previously been shown to have no significant effects on COX‐1 or COX‐2 (<a href="./references#CD012637-bbs2-0100" title="SchwabJM , SchluesenerHJ , LauferS . COX‐3: just another COX or the solitary elusive target of paracetamol?. Lancet2003;361(9362):981‐2. [DOI: 10.1016/S0140‐6736(03)12841‐3] ">Schwab 2003</a>), but is now being considered as a selective COX‐2 inhibitor (<a href="./references#CD012637-bbs2-0062" title="HinzB , ChereminaO , BruneK . Acetaminophen (paracetamol) is a selective cyclooxygenase‐2 inhibitor in man. Federation of American Societies for Experimental Biology Journal2008;22(2):383‐90. [DOI: 10.1096/fj.07‐8506com] ">Hinz 2008</a>). Significant paracetamol‐induced inhibition of prostaglandin production has been demonstrated in tissues in the brain, spleen, and lung (<a href="./references#CD012637-bbs2-0021" title="BottingRM . Mechanism of action of acetaminophen: is there a cyclooxygenase 3?. Clinical Infectious Diseases2000;31(5):S203‐10. [DOI: 10.1086/317520] ">Botting 2000</a>; <a href="./references#CD012637-bbs2-0047" title="FlowerRJ , VaneJR . Inhibition of prostaglandin synthetase in brain explains the anti‐pyretic activity of paracetamol (4‐acetamidophenol). Nature1972;240(5381):410‐1. [PUBMED: 4564318] ">Flower 1972</a>). A 'COX‐3 hypothesis', wherein the efficacy of paracetamol is attributed to its specific inhibition of a third COX isoform enzyme, COX‐3 (<a href="./references#CD012637-bbs2-0021" title="BottingRM . Mechanism of action of acetaminophen: is there a cyclooxygenase 3?. Clinical Infectious Diseases2000;31(5):S203‐10. [DOI: 10.1086/317520] ">Botting 2000</a>; <a href="./references#CD012637-bbs2-0027" title="ChandrasekharanNV , DaiH , RoosKL , EvansonNK , TomsikJ , EltonTS , et al. COX‐3, a cyclooxygenase‐1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proceedings of the National Academy of Sciences of the United States of America2002;99(21):13926‐31. [DOI: 10.1073/pnas.162468699] ">Chandrasekharan 2002</a>), now has little credibility, and a central mode action of paracetamol is thought to be likely (<a href="./references#CD012637-bbs2-0049" title="GrahamGG , ScottKF . Mechanism of action of paracetamol. American Journal of Therapeutics2005;12(1):46‐55. [DOI: 10.1097/00045391‐200501000‐00008] ">Graham 2005</a>). Paracetamol metabolism is subject to genetic variation (<a href="./references#CD012637-bbs2-0115" title="ZhaoL , PickeringG . Paracetamol metabolism and related genetic differences. Drug Metabolism Reviews2011;43(1):41‐52. [DOI: 10.3109/03602532.2010.527984] ">Zhao 2011</a>). </p> <p>There is some experimental research in rats to suggest that paracetamol may have an effect in neuropathic pain via cannabinoid receptors (<a href="./references#CD012637-bbs2-0030" title="Curros‐CriadoMM , HerreroJF . Antinociceptive effects of NCX‐701 (nitro‐paracetamol) in neuropathic rats: enhancement of antinociception by co‐administration with gabapentin. British Journal of Pharmacology2009;158(2):601‐9. [DOI: 10.1111/j.1476‐5381.2009.00343.x] ">Curros‐Criado 2009</a>; <a href="./references#CD012637-bbs2-0031" title="DaniM , GuindonJ , LambertC , BeaulieuP . The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors. European Journal of Pharmacology2007;573(1‐3):214‐5. [DOI: 10.1016/j.ejphar.2007.07.012] ">Dani 2007</a>). One single case report suggested intravenous paracetamol was effective for phantom limb pain (<a href="./references#CD012637-bbs2-0050" title="GulcuN , KaraaslanK , OzturanKE , KocogluH . Intravenous paracetamol for pain relief in a patient with neuropathic pain. Acta Anaesthesiologica Scandinavica2007;51(7):956‐7. [DOI: 10.1111/j.1399‐6576.2007.01362.x] ">Gulcu 2007</a>). </p> </section> <section id="CD012637-sec-0055"> <h3 class="title" id="CD012637-sec-0055">Why it is important to do this review</h3> <p>A previous Cochrane review examined the evidence for NSAIDs or paracetamol, alone or combined with opioids, for cancer pain (<a href="./references#CD012637-bbs2-0116" title="McNicolED , StrasselsS , GoudasL , LauJ , CarrDB . NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD005180.pub2] ">McNicol 2015</a>), with the last search date in 2005. There have been few subsequent systematic reviews of the evidence. Nabal found little evidence of efficacy for combinations with opioids (<a href="./references#CD012637-bbs2-0084" title="NabalM , LibradaS , RedondoMJ , PigniA , BrunelliC , CaraceniA . The role of paracetamol and nonsteroidal anti‐inflammatory drugs in addition to WHO Step III opioids in the control of pain in advanced cancer. A systematic review of the literature. Palliative Medicine2012;26(4):305‐12. [DOI: 10.1177/0269216311428528] ">Nabal 2012</a>). A review of paracetamol and NSAIDs concluded that while the role of these non‐opioid drugs remains controversial, the evidence for paracetamol alone was limited (<a href="./references#CD012637-bbs2-0072" title="MercadanteS , GiarratanoA . The long and winding road of nonsteroidal anti‐inflammatory drugs and paracetamol in cancer pain management: a critical review. Critical Reviews in Oncology/Hematology2013;87:140‐5. [DOI: 10.1016/j.critrevonc.2013.01.001] ">Mercadante 2013</a>). </p> <p>The evidence of effectiveness of the WHO pain ladder for cancer has been examined several times in the past two decades. These studies reported varying degrees of success, typically between 20% and 100% of people with cancer pain achieving good relief (<a href="./references#CD012637-bbs2-0016" title="Azevedo São Leão FerreiraK , KimuraM , Jacobsen TeixeiraM . The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it?. Support Care Cancer2006;14(11):1086‐93. [DOI: 10.1016/j.critrevonc.2013.01.001] ">Azevedo São Leão Ferreira 2006</a>; <a href="./references#CD012637-bbs2-0026" title="CarlsonCL . Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review. Journal of Pain Research2016;9:515‐34. [10.2147/JPR.S97759. eCollection 2016] ">Carlson 2016</a>; <a href="./references#CD012637-bbs2-0065" title="JadadAR , BrowmanGP . The WHO analgesic ladder for cancer pain management. Stepping up the quality of Its evaluation. JAMA1995;274(23):1870‐3. ">Jadad 1995</a>), with some suggesting that as many as 50% of people with cancer pain are undertreated (<a href="./references#CD012637-bbs2-0033" title="DeandreaS , MontanariM , MojaL , ApoloneG . Prevalence of undertreatment in cancer pain. A review of published literature. Annals of Oncology2008;19(12):1985‐91. [DOI: 10.1093/annonc/mdn419] ">Deandrea 2008</a>). </p> <p>In many countries, opioids are severely restricted, if available at all. This means that many people with cancer will have considerable pain and suffering unless non‐opioid analgesics can be used. This review was designed with the intention of informing policy makers such as the WHO on the possible utility of paracetamol to treat cancer‐related pain. It is hoped that the review will inform patients and carers on the value or otherwise of paracetamol in this context. </p> <p>Other relevant Cochrane reviews include an assessment of codeine alone and with paracetamol (<a href="./references#CD012637-bbs2-0101" title="StraubeC , DerryS , JacksonKC , WiffenPJ , BellRF , StrasselsS , et al. Codeine, alone and with paracetamol (acetaminophen), for cancer pain. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD006601.pub4] ">Straube 2014</a>), and an evaluation of tramadol alone and with paracetamol (<a href="./references#CD012637-bbs2-0113" title="WiffenPJ , DerryS , MooreRA . Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD012508] ">Wiffen 2017</a>). For our purposes we wanted to assess any additional efficacy of paracetamol by comparing paracetamol plus opioid with the same dose of opioid alone, a different question to that addressed by those reviews. A number of other reviews have evaluated the evidence for opioids, including buprenorphine (<a href="./references#CD012637-bbs2-0098" title="Schmidt‐HansenM , BromhamN , TaubertM , ArnoldS , HilgartJS . Buprenorphine for treating cancer pain. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD009596.pub4] ">Schmidt‐Hansen 2015a</a>), transdermal fentanyl (<a href="./references#CD012637-bbs2-0057" title="HadleyG , DerryS , MooreRA , WiffenPJ . Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010270.pub2] ">Hadley 2013</a>), hydromorphone (<a href="./references#CD012637-bbs2-0017" title="BaoYJ , HouW , KongXY , YangL , XiaJ , HuaBJ , et al. Hydromorphone for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD011108.pub2] ">Bao 2016</a>), morphine (<a href="./references#CD012637-bbs2-0112" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a>), oxycodone (<a href="./references#CD012637-bbs2-0099" title="Schmidt‐HansenM , BennettMI , ArnoldS , BromhamN , HilgartJS . Oxycodone for cancer‐related pain. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD003870.pub5] ">Schmidt‐Hansen 2015b</a>), and tapentadol (<a href="./references#CD012637-bbs2-0111" title="WiffenPJ , DerryS , NaessensK , BellRF . Oral tapentadol for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD011460.pub2] ">Wiffen 2015</a>). </p> <p>The standards used to assess evidence in pain trials have changed substantially in recent years, with particular attention being paid to trial duration, withdrawals, and statistical imputation following withdrawal, all of which can substantially alter estimates of efficacy (<a href="./references#CD012637-bbs2-0080" title="MooreRA . What works for whom? Determining the efficacy and harm of treatments for pain. Pain2013;154 Suppl 1:S77‐86. [DOI: 10.1016/j.pain.2013.03.024] ">Moore 2013b</a>). The most important change is the move away from using mean pain scores, or mean change in pain scores, to the number of people who have a large decrease in pain (by at least 50%) (<a href="./references#CD012637-bbs2-0042" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] ">Dworkin 2008</a>; <a href="./references#CD012637-bbs2-0079" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013a</a>). Pain intensity reduction of 50% or more correlates with improvements in comorbid symptoms, function, and quality of life generally (<a href="./references#CD012637-bbs2-0081" title="MooreRA , DerryS , TaylorRS , StraubeS , PhillipsCJ . The costs and consequences of adequately managed chronic non‐cancer pain and chronic neuropathic pain. Pain Practice2014;14(1):79‐94. [DOI: 10.1111/papr.12050] ">Moore 2014</a>). These standards are set out in the PaPaS author and referee guidance for pain studies of the Cochrane Pain, Palliative and Supportive Care Group (<a href="./references#CD012637-bbs2-0089" title="CochranePain , Palliative and Supportive Care Group. PaPaS author and referee guidance. papas.cochrane.org/papas‐documents (accessed 21 November 2016). ">PaPaS 2012</a>). </p> <p>Three additional issues potentially affect how evidence is evaluated.</p> <p>The first issue is study size and the overall amount of information available for analysis. There are issues over both random chance effects with small amounts of data, and potential bias in small studies, especially in pain (<a href="./references#CD012637-bbs2-0034" title="DechartresA , TrinquartL , BoutronI , RavaudP . Influence of trial sample size on treatment effect estimates: meta‐epidemiological study. BMJ2013;346:f2304. [DOI: 10.1136/bmj.f2304] ">Dechartes 2013</a>; <a href="./references#CD012637-bbs2-0035" title="DechartresA , AltmanDG , TrinquartL , BoutronI , RavaudP . Association between analytic strategy and estimates of treatment outcomes in meta‐analyses. JAMA2014;312:623‐30. [DOI: 10.1001/jama.2014.8166] ">Dechartres 2014</a>; <a href="./references#CD012637-bbs2-0045" title="FanelliD , CostasR , IoannidisJP . Meta‐assessment of bias in science. Proceedings of the National Academy of Sciences of the United States of America2017; Vol. 114, issue 14:3714‐9. [DOI: 10.1073/pnas.1618569114] ">Fanelli 2017</a>; <a href="./references#CD012637-bbs2-0075" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>; <a href="./references#CD012637-bbs2-0085" title="NguyenTL , CollinsGS , LamyA , DevereauxPJ , DaurèsJP , LandaisP , et al. Simple randomization did not protect against bias in smaller trials. Journal of Clinical Epidemiology2017;84:105‐13. [DOI: 10.1016/j.jclinepi.2017.02.010] ">Nguyen 2017</a>; <a href="./references#CD012637-bbs2-0088" title="NüeschE , TrelleS , ReichenbachS , RutjesAW , TschannenB , AltmanDG , et al. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJ2010;341:c3515. [DOI: 10.1136/bmj.c3515] ">Nüesch 2010</a>; <a href="./references#CD012637-bbs2-0102" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis ‐ a simulation study. PLOS One2011;6(10):e25491. [DOI: 10.1371/journal.pone.0025491] ">Thorlund 2011</a>). Cochrane reviews have been criticised for perhaps overemphasising results of underpowered studies or analyses (<a href="./references#CD012637-bbs2-0013" title="AlBalawiZ , McAlisterFA , ThorlundK , WongM , WetterslevJ . Random error in cardiovascular meta‐analyses: how common are false positive and false negative results?. Interational Journal of Cardiology2013;168(2):1102‐7. [DOI: 10.1016/j.ijcard.2012.11.048] ">AlBalawi 2013</a>; <a href="./references#CD012637-bbs2-0104" title="TurnerRM , BirdSM , HigginsJP . The impact of study size on meta‐analyses: examination of underpowered studies in Cochrane reviews. PLOS One2013;8(3):e59202. [DOI: 10.1371/journal.pone.0059202] ">Turner 2013</a>). On the other hand, it may be unethical to ignore potentially important information from small studies or to randomise more participants if a meta‐analysis including small, existing studies provided conclusive evidence. In this review, we have therefore chosen to limit analyses to studies with a minimum of 25 participants randomised per treatment group, which we believe has not been done previously. </p> <p>The second issue is that of study duration. Previous reviews have examined studies of any duration, even in some cases single‐dose studies, or studies lasting one day or less, often with intravenous or intramuscular formulations (<a href="./references#CD012637-bbs2-0116" title="McNicolED , StrasselsS , GoudasL , LauJ , CarrDB . NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD005180.pub2] ">McNicol 2015</a>; <a href="./references#CD012637-bbs2-0072" title="MercadanteS , GiarratanoA . The long and winding road of nonsteroidal anti‐inflammatory drugs and paracetamol in cancer pain management: a critical review. Critical Reviews in Oncology/Hematology2013;87:140‐5. [DOI: 10.1016/j.critrevonc.2013.01.001] ">Mercadante 2013</a>). While short term studies and non‐oral formulations may have some relevance in some circumstances, they have little relevance to the vast majority of people with cancer pain who will be treated with oral paracetamol over weeks, months, or even years. We have therefore chosen to include only studies with five days' duration or longer. </p> <p>The third issue is that of comparators. Many cancer pain studies involve direct comparisons of one or more formulations of the same drug, as particularly noted for oral morphine (<a href="./references#CD012637-bbs2-0112" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a>). This type of design has limited importance in evaluating the analgesic contribution of a drug, if that is not already well‐established (<a href="./references#CD012637-bbs2-0070" title="McQuayHJ , MooreRA . Placebo. Postgraduate Medical Journal2005;81(953):155‐60. ">McQuay 2005</a>). For that reason, we have limited this review to the two comparators that speak to the efficacy of paracetamol in cancer pain, namely the comparison of paracetamol versus placebo, and paracetamol plus opioid versus the same dose of opioid alone. The latter comparison would be similar to methods used for determining dose‐response of analgesics in acute pain (<a href="./references#CD012637-bbs2-0071" title="McQuayHJ , MooreRA . Dose‐response in direct comparisons of different doses of aspirin, ibuprofen and paracetamol (acetaminophen) in analgesic studies. British Journal of Clinical Pharmacology2007;63(3):271‐8. ">McQuay 2007</a>), or caffeine as an analgesic adjuvant in acute pain (<a href="./references#CD012637-bbs2-0038" title="DerryCJ , DerryS , MooreRA . Caffeine as an analgesic adjuvant for acute pain in adults. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD009281.pub3] ">Derry 2014</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012637-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012637-sec-0056"></div> <p>To assess the efficacy of oral paracetamol (acetaminophen) for cancer pain in adults and children, and the adverse events reported during its use in clinical trials. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012637-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012637-sec-0057"></div> <section id="CD012637-sec-0058"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012637-sec-0059"> <h4 class="title">Types of studies</h4> <p>To be included, studies had to:</p> <p> <ul id="CD012637-list-0001"> <li> <p>be randomised (described as 'randomised' anywhere in the manuscript);</p> </li> <li> <p>ideally be double‐blind, but we would have included single‐blind or open studies because we expected there to be a limited literature on this important topic, and we desired to be as inclusive as possible; </p> </li> <li> <p>include a minimum of 25 participants randomised per treatment arm; for cross‐over studies this meant a minimum of 25 participants at the initial randomisation. </p> </li> <li> <p>have a study duration of at least five days of continuous treatment, with outcomes reported at the end of that period. </p> </li> </ul> </p> <p>We excluded non‐randomised studies, studies of experimental pain, case reports and clinical observations. Studies had to be fully published or available as extended abstracts (e.g. from clinical trial websites); we excluded short (usually conference) abstracts as these are often unreliable (<a href="./references#CD012637-bbs2-0089" title="CochranePain , Palliative and Supportive Care Group. PaPaS author and referee guidance. papas.cochrane.org/papas‐documents (accessed 21 November 2016). ">PaPaS 2012</a>). </p> </section> <section id="CD012637-sec-0060"> <h4 class="title">Types of participants</h4> <p>We included studies of adults with cancer pain of any intensity. We did not find any eligible studies in children. We did not consider postsurgical pain or specific neuropathic pain conditions. </p> </section> <section id="CD012637-sec-0061"> <h4 class="title">Types of interventions</h4> <p>Orally administered paracetamol for cancer pain, where paracetamol alone was compared with placebo, or where paracetamol was combined with an opioid and compared with the same dose of opioid alone. </p> </section> <section id="CD012637-sec-0062"> <h4 class="title">Types of outcome measures</h4> <p>Pain had to be measured using a validated assessment tool. For pain intensity, for example, this could be a 100 mm visual analogue scale (VAS) or 11‐point numerical rating scale (no pain to worst pain imaginable), or a four‐point categorical scale (none, mild, moderate, severe), and for pain relief, for example, this could be a 100 mm VAS (no relief to complete relief), or five‐point categorical scale (none, a little, some, a lot, complete or words to that effect). Measures of 30% or greater (moderate) and 50% or greater (substantial) reduction of pain over baseline are recommended outcomes for chronic pain studies from the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) (<a href="./references#CD012637-bbs2-0042" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] ">Dworkin 2008</a>). </p> <p>A 30% or greater reduction of pain from baseline corresponds to much or very much improved on Patient Global Impression of Change (PGIC), and 50% or greater reduction corresponds to very much or completely improved. We would also use results equivalent to no pain or mild pain, because these are also outcomes acceptable to people with various types of pain (<a href="./references#CD012637-bbs2-0079" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013a</a>). </p> <section id="CD012637-sec-0063"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012637-list-0002"> <li> <p>Number of participants with pain reduction of 50% or greater from baseline.</p> </li> <li> <p>Number of participants with pain reduction of 30% or greater from baseline.</p> </li> <li> <p>Number of participants with pain no worse than mild (<a href="./references#CD012637-bbs2-0079" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013a</a>). </p> </li> <li> <p>Number of participants with PGIC much improved or very much improved (or equivalent wording). </p> </li> </ul> </p> </section> <section id="CD012637-sec-0064"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012637-list-0003"> <li> <p>Quality of life.</p> </li> <li> <p>Use of rescue medication.</p> </li> <li> <p>Participant satisfaction or preference.</p> </li> <li> <p>Serious adverse events, including death.</p> </li> <li> <p>Other adverse events, particularly reports of effects of treatment on somnolence, appetite, or thirst (<a href="./references#CD012637-bbs2-0110" title="WiffenPJ , DerryS , MooreRA . Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database of Systematic Reviews2014, Issue 5. [DOI: 10.1002/14651858.CD011056.pub2] ">Wiffen 2014</a>). </p> </li> <li> <p>Withdrawals due to lack of efficacy, adverse events, or any cause.</p> </li> </ul> </p> </section> </section> </section> <section id="CD012637-sec-0065"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012637-sec-0066"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases without language or date restrictions.</p> <p> <ul id="CD012637-list-0004"> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) (via CRSO) on 27 March 2017. </p> </li> <li> <p>MEDLINE (via Ovid) from 1946 to 27 March 2017.</p> </li> <li> <p>Embase (via Ovid) from 1974 to 27 March 2017.</p> </li> </ul> </p> <p>We used a combination of MeSH (or equivalent) and text word terms and tailored search strategies to individual databases. The search strategies for CENTRAL, MEDLINE, and Embase are in <a href="./appendices#CD012637-sec-0127">Appendix 1</a>, <a href="./appendices#CD012637-sec-0128">Appendix 2</a>, and <a href="./appendices#CD012637-sec-0129">Appendix 3</a>, respectively. </p> </section> <section id="CD012637-sec-0067"> <h4 class="title">Searching other resources</h4> <p>We searched the metaRegister of controlled trials in ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) and the WHO International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>) for unpublished and ongoing trials. In addition, we checked reference lists of reviews and retrieved articles for additional studies and performed citation searches on key articles. We did not contact authors for additional information. </p> </section> </section> <section id="CD012637-sec-0068"> <h3 class="title" id="CD012637-sec-0068">Data collection and analysis</h3> <section id="CD012637-sec-0069"> <h4 class="title">Selection of studies</h4> <p>Two review authors (RAM, SD) independently read the abstract of each study identified by the search, eliminated studies that clearly did not satisfy inclusion criteria, and obtained full copies of the remaining studies. Two review authors (RAM, SD) then read these studies independently to select relevant studies for inclusion. In the event of disagreement, a third review author (PW) was available to adjudicate. We did not anonymise the studies before assessment. We have included a PRISMA flow chart in the review to show the status of identified studies as recommended in Section 11.2.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012637-bbs2-0061" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We included studies in the review if they satisfied our inclusion criteria, irrespective of whether measured outcome data were reported in a 'usable' way. </p> </section> <section id="CD012637-sec-0070"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (RAM, SD) independently extracted data using a standard form and checked for agreement before entry into Review Manager (RevMan) (<a href="./references#CD012637-bbs2-0094" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We included information about the number of participants treated and demographic details, type of cancer, drug and dosing regimen, study design (placebo or active control) and methods, study duration and follow‐up, analgesic outcome measures and results, withdrawals and adverse events. If necessary, we would have collated multiple reports of the same study, so that each study rather than each report was the unit of interest in the review. We collected characteristics of the included studies in sufficient detail to complete a <a href="./references#CD012637-sec-0143" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD012637-sec-0071"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (RAM, SD) independently assessed risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Chapter 8, <a href="http://archie.cochrane.org/sections/documents/view?version=z1701111321125315331878489805618%26format=REVMAN#REF-Higgins-2011" target="_blank">Higgins 2011</a>) and adapted from those used by the Cochrane Pregnancy and Childbirth Group, with any disagreements resolved by discussion. We completed a 'Risk of bias' table for each included study using the 'Risk of bias' tool in RevMan (<a href="http://archie.cochrane.org/sections/documents/view?version=z1701111321125315331878489805618%26format=REVMAN#REF-RevMan-2014" target="_blank">RevMan 2014</a>). </p> <p>We assessed the following for each study.</p> <p> <ul id="CD012637-list-0005"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, e.g. random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies using a non‐random process (e.g. odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during, recruitment or changed after assignment. We assessed the methods as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); unclear risk of bias (method not clearly stated); high risk of bias, where study did not conceal allocation (e.g. open list). </p> </li> <li> <p>Blinding of participants and personnel (checking for possible performance bias). We assessed the methods used to blind study participants and personnel from knowledge of which intervention a participant received. We assessed methods as: low risk of bias (study stated that it was blinded and described the method used to achieve blinding, such as identical tablets matched in appearance or smell, or a double‐dummy technique); unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved); high risk of bias (study participants or personnel, or both, not blinded). </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study had a clear statement that outcome assessors were unaware of treatment allocation, and ideally described how this was achieved); unclear risk of bias (study stated that outcome assessors were blind to treatment allocation but lacked a clear statement on how it was achieved); high risk of bias (outcome assessment not blinded). </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk (fewer than 10% of participants did not complete the study or used ‘baseline observation carried forward’ analysis, or both); unclear risk of bias (used 'last observation carried forward' analysis); high risk of bias (used 'completer' analysis). </p> </li> <li> <p>Reporting bias due to selective outcome reporting (reporting bias). We checked if an a priori study protocol was available and if all outcomes of the study protocol were reported in the publications of the study. We assessed the methods used to deal with incomplete data as: low risk of reporting bias if the study protocol was available and all of the study’s prespecified (primary and secondary) outcomes that were of interest in the review were reported in the pre‐specified way, or if the study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were pre‐specified (convincing text of this nature may be uncommon); high risk of reporting bias if not all of the study’s pre‐specified primary outcomes were reported; one or more primary outcomes was reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre‐specified; one or more reported primary outcomes were not pre‐specified (unless clear justification for their reporting was provided, such as an unexpected adverse effect); one or more outcomes of interest in the review were reported incompletely so that they could not be entered in a meta‐analysis; the study report did not include results for a key outcome that would be expected to have been reported for such a study; and unclear risk of bias risk of bias if insufficient information is available to permit judgement of ‘Low risk’ or ‘High risk’. </p> </li> <li> <p>Size of study (checking for possible biases confounded by small size (<a href="./references#CD012637-bbs2-0034" title="DechartresA , TrinquartL , BoutronI , RavaudP . Influence of trial sample size on treatment effect estimates: meta‐epidemiological study. BMJ2013;346:f2304. [DOI: 10.1136/bmj.f2304] ">Dechartes 2013</a>; <a href="./references#CD012637-bbs2-0035" title="DechartresA , AltmanDG , TrinquartL , BoutronI , RavaudP . Association between analytic strategy and estimates of treatment outcomes in meta‐analyses. JAMA2014;312:623‐30. [DOI: 10.1001/jama.2014.8166] ">Dechartres 2014</a>; <a href="./references#CD012637-bbs2-0075" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>; <a href="./references#CD012637-bbs2-0088" title="NüeschE , TrelleS , ReichenbachS , RutjesAW , TschannenB , AltmanDG , et al. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJ2010;341:c3515. [DOI: 10.1136/bmj.c3515] ">Nüesch 2010</a>; <a href="./references#CD012637-bbs2-0102" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis ‐ a simulation study. PLOS One2011;6(10):e25491. [DOI: 10.1371/journal.pone.0025491] ">Thorlund 2011</a>)). We assessed studies as being at low risk of bias (200 participants or more per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (fewer than 50 participants per treatment arm). </p> </li> </ul> </p> </section> <section id="CD012637-sec-0072"> <h4 class="title">Measures of treatment effect</h4> <p>We planned to use dichotomous data to calculate risk difference (RD) or risk ratio (RR) with 95% confidence intervals (CIs) using a fixed‐effect model, and calculate numbers needed to treat for one additional beneficial outcome (NNT) as the reciprocal of the absolute risk reduction (<a href="./references#CD012637-bbs2-0069" title="McQuayH , MooreA . An Evidence‐based Resource for Pain Relief. Oxford: Oxford University Press, 1998. [ISBN: 0‐19‐263048‐2] ">McQuay 1998</a>). For unwanted effects, the number needed to treat becomes the number needed to treat for one additional harmful outcome (NNH), and is calculated in the same manner. </p> <p>We planned to use the following terms to describe adverse outcomes in terms of harm or prevention of harm. </p> <p> <ul id="CD012637-list-0006"> <li> <p>When significantly fewer adverse outcomes occurred with paracetamol than with control (placebo or active control), we used the term number needed to treat to prevent one event (NNTp). </p> </li> <li> <p>When significantly more adverse outcomes occurred with paracetamol compared with control (placebo or active control) we used the term number needed to treat for an additional harmful outcome or cause one event (NNH). </p> </li> </ul> </p> <p>We did not plan to use continuous data for the primary outcome because it is inappropriate where there is an underlying skewed distribution, as is usually the case with analgesic response. </p> </section> <section id="CD012637-sec-0073"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of randomisation was the individual participant.</p> </section> <section id="CD012637-sec-0074"> <h4 class="title">Dealing with missing data</h4> <p>We planned to use intention‐to‐treat (ITT) analyses: participants who were randomised, took the study medication, and gave a minimum of one post‐baseline assessment. We have reported per‐protocol data in the absence of ITT data. </p> </section> <section id="CD012637-sec-0075"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess statistical heterogeneity using L'Abbé plots, a visual method for assessing differences in results of individual studies (<a href="http://archie.cochrane.org/sections/documents/view?version=z1701111321125315331878489805618%26format=REVMAN#REF-L_x0027_Abb_x00e9_-1987" target="_blank">L'Abbé 1987</a>), and by use of the I<sup>2</sup> statistic. We anticipated that there could be an effect of differences between participants, environment (inpatient versus outpatient), and outcome measures. We planned to explore these with subgroup and sensitivity analyses where there were sufficient data, recognising the difficulties of assessing heterogeneity with small numbers of small studies (<a href="./references#CD012637-bbs2-0048" title="GavaghanDJ , MooreRA , McQuayHJ . An evaluation of homogeneity tests in meta‐analyses in pain using simulations of individual patient data. Pain2000;85(3):415‐24. ">Gavaghan 2000</a>; <a href="./references#CD012637-bbs2-0064" title="IntHoutJ , IoannidisJP , BormGF , GoemanJJ . Small studies are more heterogeneous than large ones: a meta‐meta‐analysis. Journal of Clinical Epidemiology2015;68:860‐9. [DOI: 10.1016/j.jclinepi.2015.03.017] ">IntHout 2015</a>). In the event, there were insufficient data to assess heterogeneity. </p> </section> <section id="CD012637-sec-0076"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to use dichotomous data of known utility (<a href="./references#CD012637-bbs2-0077" title="MooreRA , MooreOA , DerryS , PelosoPM , GammaitoniAR , WangH . Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases2010;69(2):374‐9. [DOI: 10.1136/ard.2009.107805] ">Moore 2010a</a>; <a href="./references#CD012637-bbs2-0079" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013a</a>). The review would not depend on what additional information authors of the original studies chose to report or not. </p> <p>We planned to undertake an assessment of publication bias if there were sufficient data for meta‐analysis, using a method designed to detect the amount of unpublished data with a null effect required to make any result clinically irrelevant (usually taken to mean an NNT of 10 or higher) (<a href="./references#CD012637-bbs2-0076" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978–0–931092–69–5] ">Moore 2008</a>). In the event, there were insufficient data to assess publication bias. </p> </section> <section id="CD012637-sec-0077"> <h4 class="title">Data synthesis</h4> <p>We planned to undertake a quantitative synthesis and present data in forest plots if there were sufficient data. In the event of substantial clinical heterogeneity, we would switch off the totals in the forest plots. </p> <p> <ul id="CD012637-list-0007"> <li> <p>We would undertake a meta‐analysis only if participants, interventions, comparisons, and outcomes were judged to be sufficiently similar to ensure an answer that is clinically meaningful. </p> </li> <li> <p>We would undertake a meta‐analysis only where there were data from at least two studies and 200 participants for analysis. </p> </li> <li> <p>We planned to use RevMan for meta‐analysis (<a href="./references#CD012637-bbs2-0094" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) and Excel for NNT and NNH. </p> </li> </ul> </p> <p>In the event, there were insufficient data for pooling of data for any outcome.</p> <section id="CD012637-sec-0078"> <h5 class="title">Quality of the evidence</h5> <p>We used the GRADE system to assess the quality of the evidence related to the key outcomes listed in <a href="#CD012637-sec-0062">Types of outcome measures</a>, as appropriate (<a href="./appendices#CD012637-sec-0130">Appendix 4</a>). Two review authors (RAM, SD) independently rated the evidence for each outcome. </p> <p>We paid particular attention to inconsistency, where point estimates vary widely across studies or confidence intervals (CIs) of studies show minimal or no overlap (<a href="./references#CD012637-bbs2-0054" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence ‐ inconsistency. Journal of Cinical Epidemiology2011;64(12):1294‐302. [DOI: 10.1016/j.jclinepi.2011.03.017] ">Guyatt 2011</a>), and to the potential for publication bias, based on the amount of unpublished data required to make the result clinically irrelevant (<a href="./references#CD012637-bbs2-0076" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978–0–931092–69–5] ">Moore 2008</a>). </p> <p>Lastly, there may be circumstances where the overall rating for a particular outcome needs to be adjusted as recommended by GRADE guidelines (<a href="./references#CD012637-bbs2-0055" title="GuyattG , OxmanAD , SultanS , BrozekJ , GlasziouP , Alonso‐CoelloP , et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology2013;66:151‐7. [DOI: 10.1016/j.jclinepi.2012.01.006] ">Guyatt 2013a</a>). For example, if there are so few data that the results are highly susceptible to the random play of chance, or if a study uses last observation carried forward (LOCF) imputation in circumstances where there are substantial differences in adverse event withdrawals, one would have no confidence in the result, and would need to downgrade the quality of the evidence by three levels, to very low quality. In circumstances where there were no data reported for an outcome, we have reported the level of evidence as very low quality (<a href="./references#CD012637-bbs2-0056" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing summary of findings tables ‐ binary outcomes. Journal of Clinical Epidemiology2013;66:158‐72. [DOI: 10.1016/j.jclinepi.2012.01.012] ">Guyatt 2013b</a>). </p> <p>In addition, we are aware that many Cochrane reviews are based largely or wholly on small underpowered studies, and that there is a danger of drawing erroneous conclusions of evidence based on inadequate information (<a href="./references#CD012637-bbs2-0013" title="AlBalawiZ , McAlisterFA , ThorlundK , WongM , WetterslevJ . Random error in cardiovascular meta‐analyses: how common are false positive and false negative results?. Interational Journal of Cardiology2013;168(2):1102‐7. [DOI: 10.1016/j.ijcard.2012.11.048] ">AlBalawi 2013</a>; <a href="./references#CD012637-bbs2-0023" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [DOI: 10.1093/ije/dyn188] ">Brok 2009</a>; <a href="./references#CD012637-bbs2-0095" title="RobertsI , KerK , EdwardsP , BeecherD , MannoD , SydenhamE . The knowledge system underpinning healthcare is not fit for purpose and must change. BMJ2015;350:h2463. [DOI: 10.1136/bmj.h2463] ">Roberts 2015</a>; <a href="./references#CD012637-bbs2-0104" title="TurnerRM , BirdSM , HigginsJP . The impact of study size on meta‐analyses: examination of underpowered studies in Cochrane reviews. PLOS One2013;8(3):e59202. [DOI: 10.1371/journal.pone.0059202] ">Turner 2013</a>). </p> </section> <section id="CD012637-sec-0079"> <h5 class="title">'Summary of findings' table</h5> <p>We have included a 'Summary of findings' table as set out in the Pain, Palliative and Supportive Care Review Group author guide (<a href="./references#CD012637-bbs2-0089" title="CochranePain , Palliative and Supportive Care Group. PaPaS author and referee guidance. papas.cochrane.org/papas‐documents (accessed 21 November 2016). ">PaPaS 2012</a>) and recommended in Chapter 4.6.6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012637-bbs2-0061" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We present the main findings in a simple tabular format, to include key information concerning the quality of evidence, the magnitude of effect of the interventions examined, the sum of available data on the outcomes of at least 30% and at least 50% pain relief, PGIC much or very much improved, pain no worse than mild at one or two weeks, adverse events, and serious adverse events. In addition, we have also included other measures of efficacy or harm (mean pain intensity at end of study, quality of life or well‐being at end of treatment, and patient satisfaction or preference). </p> <p>For the 'Summary of findings' table we used the following descriptors for levels of evidence (<a href="./references#CD012637-bbs2-0044" title="EffectivePractice , Organisation of Care(EPOC) . 23. Worksheets for preparing a Summary of Findings using GRADE. Resources for review authors. epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 30 November 2016). ">EPOC 2015</a>). </p> <section id="CD012637-sec-0080"> <h6 class="title">High:</h6> <p>This research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is low. </p> </section> <section id="CD012637-sec-0081"> <h6 class="title">Moderate:</h6> <p>This research provides a good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is moderate. </p> </section> <section id="CD012637-sec-0082"> <h6 class="title">Low:</h6> <p>This research provides some indication of the likely effect. However, the likelihood that it will be substantially different<sup>†</sup> is high. </p> </section> <section id="CD012637-sec-0083"> <h6 class="title">Very low:</h6> <p>This research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is very high. </p> <p><sup>†</sup> Substantially different: a large enough difference that it might affect a decision. </p> </section> </section> </section> <section id="CD012637-sec-0084"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned several possible subgroup analyses, depending on the availability of data.</p> <p> <ul id="CD012637-list-0008"> <li> <p>Because we expected that many studies would have a cross‐over design that could impede meta‐analysis (<a href="./references#CD012637-bbs2-0043" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>), we planned to examine cross‐over and parallel‐group designs separately. </p> </li> <li> <p>We planned to investigate whether subgroup analysis by dose of paracetamol (up to 2000 mg/day, 2001 mg/day to 4000 mg/day) was possible. </p> </li> <li> <p>We planned to analyse separately studies with paracetamol alone, and paracetamol combined with opioid. We anticipated that these studies might also reflect different levels of initial pain intensity. </p> </li> </ul> </p> <p>We planned no other subgroup analyses because the data were expected to be sparse, with small numbers of small trials. In the event, there were insufficient data for any subgroup analysis. </p> </section> <section id="CD012637-sec-0085"> <h4 class="title">Sensitivity analysis</h4> <p>We did not plan any sensitivity analyses because the data were expected to be sparse, with small numbers of small trials. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012637-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012637-sec-0086"></div> <section id="CD012637-sec-0087"> <h3 class="title">Description of studies</h3> <section id="CD012637-sec-0088"> <h4 class="title">Results of the search</h4> <p>Searches identified 261 articles in CENTRAL, 326 articles in MEDLINE, 834 articles in Embase, and four additional study reports in clinical trial registries. After screening and assessment of relevant full texts, we included three studies and excluded six studies. </p> <p>Two studies are awaiting classification. <a href="./references#CD012637-bbs2-0010" title="VardyJ (Principal Investigator) . A randomised, placebo‐controlled, crossover trial of acetaminophen in cancer patients on strong opioids. clinicaltrials.gov/ct2/show/NCT00152854 (accessed 30 March 2017)2016. [CTG: NCT00152854] ">NCT00152854</a> has completed, but with only 12 participants and no study results posted; there were insufficient data to judge methodological criteria and it would probably be excluded because of its small size. We have been unable to obtain the full text of <a href="./references#CD012637-bbs2-0011" title="PacilioG , PizzaC , VetranoA , MastrantoniM , CeccarelliG . A double‐blind study on the effect of flupirtine as compared to paracetamol in the cancer pain. Riforma Medica1989;104(1‐2):29‐32. [EMBASE: 1989176982] ">Pacilio 1989</a>. </p> <p>One study with an estimated enrolment of 140 participants is ongoing, with an expected completion date of April 2019 (<a href="./references#CD012637-bbs2-0012" title="University of Edinburgh. A double‐blind randomised parallel group trial of paracetamol versus placebo in conjunction with strong opioids for cancer related pain. clinicaltrials.gov/ct2/show/NCT02706769 (accessed 30 March 2017)2016. ">NCT02706769</a>). This double‐blind study appears to use a randomised withdrawal design, in which participants taking daily regular strong opioids plus 4 x 1000 mg paracetamol are randomised to continue with opioid plus paracetamol or opioids alone. </p> <p><a href="#CD012637-fig-0001">Figure 1</a> illustrates the flow of studies in the review. </p> <div class="figure" id="CD012637-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012637-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012637.pub2/media/CDSR/CD012637/image_n/nCD012637-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012637-sec-0089"> <h4 class="title">Included studies</h4> <p>We included three studies (<a href="./references#CD012637-bbs2-0001" title="AxelssonB , BorupS . Is there an additive analgesic effect of paracetamol at step 3? A double‐blind randomized controlled study. Palliative Medicine2003;17(8):724‐5. [DOI: 10.1177/026921630301700816] ">Axelsson 2003</a>; <a href="./references#CD012637-bbs2-0002" title="CuberoDI , delGiglioA . Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double‐blind, placebo‐controlled study. Supportive Care in Cancer2010;18(2):235‐42. [DOI: 10.1007/s00520‐009‐0649‐8] ">Cubero 2010</a>; <a href="./references#CD012637-bbs2-0003" title="IsraelFJ , ParkerG , CharlesM , ReymondL . Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high‐dose strong opioids: a randomized, double‐blind, placebo‐controlled, crossover trial. Journal of Pain and Symptom Management2010;39(3):548‐54. [DOI: 10.1016/j.jpainsymman.2009.07.008] ">Israel 2010</a>), all of which were randomised, double‐blinded, and placebo‐controlled. They initially randomised 122 participants, of whom 95 completed the studies. </p> <p>One study (<a href="./references#CD012637-bbs2-0002" title="CuberoDI , delGiglioA . Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double‐blind, placebo‐controlled study. Supportive Care in Cancer2010;18(2):235‐42. [DOI: 10.1007/s00520‐009‐0649‐8] ">Cubero 2010</a>) used a parallel group design and had a treatment duration of one week. Two studies used a cross‐over design, with treatment periods of one week (<a href="./references#CD012637-bbs2-0001" title="AxelssonB , BorupS . Is there an additive analgesic effect of paracetamol at step 3? A double‐blind randomized controlled study. Palliative Medicine2003;17(8):724‐5. [DOI: 10.1177/026921630301700816] ">Axelsson 2003</a>) and five days (<a href="./references#CD012637-bbs2-0003" title="IsraelFJ , ParkerG , CharlesM , ReymondL . Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high‐dose strong opioids: a randomized, double‐blind, placebo‐controlled, crossover trial. Journal of Pain and Symptom Management2010;39(3):548‐54. [DOI: 10.1016/j.jpainsymman.2009.07.008] ">Israel 2010</a>). Neither cross‐over study had a washout period, but <a href="./references#CD012637-bbs2-0003" title="IsraelFJ , ParkerG , CharlesM , ReymondL . Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high‐dose strong opioids: a randomized, double‐blind, placebo‐controlled, crossover trial. Journal of Pain and Symptom Management2010;39(3):548‐54. [DOI: 10.1016/j.jpainsymman.2009.07.008] ">Israel 2010</a> stated that data from only the last four days were used in analyses to avoid carryover effects. We used results from both parts of the cross‐over. </p> <p>All studies used paracetamol as an add‐on to established treatment with strong opioids and other non‐paracetamol medication. <a href="./references#CD012637-bbs2-0002" title="CuberoDI , delGiglioA . Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double‐blind, placebo‐controlled study. Supportive Care in Cancer2010;18(2):235‐42. [DOI: 10.1007/s00520‐009‐0649‐8] ">Cubero 2010</a> switched participants abruptly ("stop/start") from stable doses of morphine to equivalent doses of methadone, with or without paracetamol. No studies tested paracetamol alone. </p> <p>Each study included both male and female participants with various types of cancer; mainly colorectal, prostate, breast, and pancreas. The mean ages ranged from 56 to 72 years (range 19 to 86). In <a href="./references#CD012637-bbs2-0001" title="AxelssonB , BorupS . Is there an additive analgesic effect of paracetamol at step 3? A double‐blind randomized controlled study. Palliative Medicine2003;17(8):724‐5. [DOI: 10.1177/026921630301700816] ">Axelsson 2003</a>, participants had baseline pain intensity on opioid treatment of less than 4/10 (median 2 on scale 0 to 3); in <a href="./references#CD012637-bbs2-0002" title="CuberoDI , delGiglioA . Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double‐blind, placebo‐controlled study. Supportive Care in Cancer2010;18(2):235‐42. [DOI: 10.1007/s00520‐009‐0649‐8] ">Cubero 2010</a>, participants had a median baseline pain intensity on treatment of 5/10 for the paracetamol arm and 3.5/10 for the placebo arm; in <a href="./references#CD012637-bbs2-0003" title="IsraelFJ , ParkerG , CharlesM , ReymondL . Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high‐dose strong opioids: a randomized, double‐blind, placebo‐controlled, crossover trial. Journal of Pain and Symptom Management2010;39(3):548‐54. [DOI: 10.1016/j.jpainsymman.2009.07.008] ">Israel 2010</a>, participants had a baseline pain intensity of at least 2/10. </p> <p>The median daily dose of oral morphine was 70 mg (range 20 mg to 440 mg) in <a href="./references#CD012637-bbs2-0001" title="AxelssonB , BorupS . Is there an additive analgesic effect of paracetamol at step 3? A double‐blind randomized controlled study. Palliative Medicine2003;17(8):724‐5. [DOI: 10.1177/026921630301700816] ">Axelsson 2003</a>, 60 mg (40 mg to 540 mg) in <a href="./references#CD012637-bbs2-0002" title="CuberoDI , delGiglioA . Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double‐blind, placebo‐controlled study. Supportive Care in Cancer2010;18(2):235‐42. [DOI: 10.1007/s00520‐009‐0649‐8] ">Cubero 2010</a>, and 225 mg (200 mg to 900 mg, plus one participant taking 9000 mg) in <a href="./references#CD012637-bbs2-0003" title="IsraelFJ , ParkerG , CharlesM , ReymondL . Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high‐dose strong opioids: a randomized, double‐blind, placebo‐controlled, crossover trial. Journal of Pain and Symptom Management2010;39(3):548‐54. [DOI: 10.1016/j.jpainsymman.2009.07.008] ">Israel 2010</a>. </p> <p>Further details are in the <a href="./references#CD012637-sec-0143" title="">Characteristics of included studies</a> table. </p> <p>Two studies are awaiting assessment. <a href="./references#CD012637-bbs2-0010" title="VardyJ (Principal Investigator) . A randomised, placebo‐controlled, crossover trial of acetaminophen in cancer patients on strong opioids. clinicaltrials.gov/ct2/show/NCT00152854 (accessed 30 March 2017)2016. [CTG: NCT00152854] ">NCT00152854</a> was a randomised, double‐blind cross‐over study in which paracetamol or placebo was added to existing opioid therapy for periods of seven days. Participants were taking at least 60 mg morphine equivalents per day. The study has completed, but we were unable to find any results, other than only 12 participants completed. <a href="./references#CD012637-bbs2-0011" title="PacilioG , PizzaC , VetranoA , MastrantoniM , CeccarelliG . A double‐blind study on the effect of flupirtine as compared to paracetamol in the cancer pain. Riforma Medica1989;104(1‐2):29‐32. [EMBASE: 1989176982] ">Pacilio 1989</a> compared paracetamol with flupirtine in cancer pain; no further details were available, and would probably not be included. </p> </section> <section id="CD012637-sec-0090"> <h4 class="title">Excluded studies</h4> <p>We excluded six studies (<a href="./references#CD012637-bbs2-0004" title="MitchellG (Principal Investigator) . A single patient multiple cross‐over study to determine the efficacy of paracetamol in relieving pain suffered by patients with advanced cancer taking regular opioids. www.anzctr.org.au/ACTRN12610000893000.aspx (accessed 30 March 2017)2010. [ANZCTR: ACTRN12610000893000] ">ACTRN12610000893000</a>; <a href="./references#CD012637-bbs2-0005" title="AxelssonB , StellbornP , StrömG . Analgesic effect of paracetamol on cancer related pain in concurrent strong opioid therapy. A prospective clinical study. Acta Oncologica2008;47(5):891‐5. [DOI: 10.1080/02841860701687259] ">Axelsson 2008</a>; <a href="./references#CD012637-bbs2-0006" title="DanningerR , JakseR , BeublerE . Randomized crossover‐comparison of 2 g‐ and 4 g‐doses of paracetamol per day in the case of mild to moderate pain caused by head and neck cancers. European Journal of Pain1993;14(1):14‐8. [EMBASE: 132642 xx] ">Danninger 1993</a>; <a href="./references#CD012637-bbs2-0007" title="Ken‐ichi Kaneko (PrincipleInvestigator) . Efficacy and safety of acetaminophen in the treatment of patients with head and neck cancer. upload.umin.ac.jp/cgi‐open‐bin/ctr_e/ctr_view.cgi?recptno=R000010522 (accessed 30 March 2017). ">JPRN‐UMIN000009292</a>; <a href="./references#CD012637-bbs2-0008" title="NicklesJ , MitchellGK , HardyJ , SeniorH , CarmontS‐A , SchluterPJ , et al. Single‐patient multiple crossover studies to determine the effectiveness of paracetamol in relieving pain suffered by patients with advanced cancer taking regular opioids: A pilot study. Palliative Medicine2016;30(8):800‐2. [ANZCTR: ACTRN12609000870257; DOI: 10.1177/0269216316635012] ">Nickles 2016</a>; <a href="./references#CD012637-bbs2-0009" title="StocklerM , VardyJ , PillaiA , WarrD . Acetaminophen (paracetamol) improves pain and well‐being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double‐blind, placebo‐controlled cross‐over trial. Journal of Clinical Oncology2004;22(16):3389‐94. [DOI: 10.1200/JCO.2004.09.122] ">Stockler 2004</a>), because the treatment periods were less than five days or they were not randomised. Further details are in the <a href="./references#CD012637-sec-0144" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD012637-sec-0091"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias in individual studies is shown in <a href="#CD012637-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD012637-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012637-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012637.pub2/media/CDSR/CD012637/image_n/nCD012637-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012637-sec-0092"> <h4 class="title">Allocation</h4> <p>All three studies were randomised, but one did not adequately describe the methods used to generate the random sequence or to conceal the allocation sequence (<a href="./references#CD012637-bbs2-0001" title="AxelssonB , BorupS . Is there an additive analgesic effect of paracetamol at step 3? A double‐blind randomized controlled study. Palliative Medicine2003;17(8):724‐5. [DOI: 10.1177/026921630301700816] ">Axelsson 2003</a>, reported as a letter). </p> </section> <section id="CD012637-sec-0093"> <h4 class="title">Blinding</h4> <p>All three studies were double‐blind, but only one adequately described the method used to maintain the blinding (<a href="./references#CD012637-bbs2-0003" title="IsraelFJ , ParkerG , CharlesM , ReymondL . Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high‐dose strong opioids: a randomized, double‐blind, placebo‐controlled, crossover trial. Journal of Pain and Symptom Management2010;39(3):548‐54. [DOI: 10.1016/j.jpainsymman.2009.07.008] ">Israel 2010</a>). </p> </section> <section id="CD012637-sec-0094"> <h4 class="title">Incomplete outcome data</h4> <p>We judged all three studies at high risk of attrition bias because they had substantial attrition (&gt; 10%) and analysed only the participants who completed the study. </p> </section> <section id="CD012637-sec-0095"> <h4 class="title">Selective reporting</h4> <p>We judged one study to have low risk of bias because there was an on‐line protocol (<a href="./references#CD012637-bbs2-0002" title="CuberoDI , delGiglioA . Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double‐blind, placebo‐controlled study. Supportive Care in Cancer2010;18(2):235‐42. [DOI: 10.1007/s00520‐009‐0649‐8] ">Cubero 2010</a>). The other two studies were at unclear risk of bias for selective reporting. We did not have access to protocols to check for missing outcomes, but all relevant outcomes specified in the publication were reported. </p> </section> <section id="CD012637-sec-0096"> <h4 class="title">Other potential sources of bias</h4> <p>All three studies included fewer than 50 participants per treatment arm and we judged them at high risk of bias due to size. </p> </section> </section> <section id="CD012637-sec-0097"> <h3 class="title" id="CD012637-sec-0097">Effects of interventions</h3> <p>See: <a href="./full#CD012637-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <section id="CD012637-sec-0098"> <h4 class="title">Efficacy</h4> <p>A summary of results for efficacy outcomes in individual studies is available in <a href="./appendices#CD012637-sec-0131">Appendix 5</a> and <a href="./full#CD012637-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD012637-sec-0099"> <h5 class="title">Pain outcomes</h5> <p>No studies tested paracetamol alone.</p> <p>None of the studies reported any of our primary outcomes: participants with pain reduction of at least 50%, and at least 30%, from baseline; participants with pain no worse than mild at the end of the treatment period; participants with PGIC of much improved or very much improved (or equivalent wording). </p> <p>All studies (93 participants analysed) reported no difference between paracetamol plus opioid and placebo plus opioid for mean pain intensity measures at the end of the treatment period. <a href="./references#CD012637-bbs2-0002" title="CuberoDI , delGiglioA . Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double‐blind, placebo‐controlled study. Supportive Care in Cancer2010;18(2):235‐42. [DOI: 10.1007/s00520‐009‐0649‐8] ">Cubero 2010</a> also found no difference between treatment arms for time to return to baseline pain intensity following an abrupt switch from morphine to methadone, either with or without paracetamol. </p> <p>We assessed this as very low‐quality evidence because of high risk of bias and small size. </p> </section> <section id="CD012637-sec-0100"> <h5 class="title">Quality of life</h5> <p>Two studies (71 participants analysed) reported that there was no difference between participants treated with paracetamol and placebo for quality of life assessments at the end of the treatment period (<a href="./references#CD012637-bbs2-0001" title="AxelssonB , BorupS . Is there an additive analgesic effect of paracetamol at step 3? A double‐blind randomized controlled study. Palliative Medicine2003;17(8):724‐5. [DOI: 10.1177/026921630301700816] ">Axelsson 2003</a>; <a href="./references#CD012637-bbs2-0002" title="CuberoDI , delGiglioA . Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double‐blind, placebo‐controlled study. Supportive Care in Cancer2010;18(2):235‐42. [DOI: 10.1007/s00520‐009‐0649‐8] ">Cubero 2010</a>). The other study (22 participants analysed) reported no difference in 'well‐being' between the interventions (<a href="./references#CD012637-bbs2-0003" title="IsraelFJ , ParkerG , CharlesM , ReymondL . Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high‐dose strong opioids: a randomized, double‐blind, placebo‐controlled, crossover trial. Journal of Pain and Symptom Management2010;39(3):548‐54. [DOI: 10.1016/j.jpainsymman.2009.07.008] ">Israel 2010</a>). </p> <p>We assessed this as very low‐quality evidence because of high risk of bias and small size. </p> </section> <section id="CD012637-sec-0101"> <h5 class="title">Use of rescue medication</h5> <p><a href="./references#CD012637-bbs2-0003" title="IsraelFJ , ParkerG , CharlesM , ReymondL . Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high‐dose strong opioids: a randomized, double‐blind, placebo‐controlled, crossover trial. Journal of Pain and Symptom Management2010;39(3):548‐54. [DOI: 10.1016/j.jpainsymman.2009.07.008] ">Israel 2010</a> reported no difference between paracetamol and placebo arms for use of rescue medication for episodes of breakthrough pain. <a href="./references#CD012637-bbs2-0002" title="CuberoDI , delGiglioA . Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double‐blind, placebo‐controlled study. Supportive Care in Cancer2010;18(2):235‐42. [DOI: 10.1007/s00520‐009‐0649‐8] ">Cubero 2010</a> used requirement for rescue medication to adjust the dose of methadone. </p> <p>We assessed this as very low‐quality evidence because of high risk of bias and small size. </p> </section> <section id="CD012637-sec-0102"> <h5 class="title">Participant satisfaction or preference</h5> <p>The two cross‐over studies reported that pain was better with paracetamol in 15/52 participants, better with placebo in 9/52 participants, and no different in 28/52 participants after five or seven days of treatment (<a href="./references#CD012637-bbs2-0001" title="AxelssonB , BorupS . Is there an additive analgesic effect of paracetamol at step 3? A double‐blind randomized controlled study. Palliative Medicine2003;17(8):724‐5. [DOI: 10.1177/026921630301700816] ">Axelsson 2003</a>; <a href="./references#CD012637-bbs2-0003" title="IsraelFJ , ParkerG , CharlesM , ReymondL . Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high‐dose strong opioids: a randomized, double‐blind, placebo‐controlled, crossover trial. Journal of Pain and Symptom Management2010;39(3):548‐54. [DOI: 10.1016/j.jpainsymman.2009.07.008] ">Israel 2010</a>). </p> <p>We assessed this as very low‐quality evidence because of high risk of bias and small size. </p> </section> </section> <section id="CD012637-sec-0103"> <h4 class="title">Harm</h4> <p>A summary of results for adverse outcomes in individual studies is available in <a href="./appendices#CD012637-sec-0132">Appendix 6</a>. </p> <section id="CD012637-sec-0104"> <h5 class="title">Serious adverse events</h5> <p>None of the studies specifically reported any serious adverse events, but there was one death due to underlying disease in <a href="./references#CD012637-bbs2-0002" title="CuberoDI , delGiglioA . Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double‐blind, placebo‐controlled study. Supportive Care in Cancer2010;18(2):235‐42. [DOI: 10.1007/s00520‐009‐0649‐8] ">Cubero 2010</a>. It was not clear which treatment the participant was receiving. </p> <p>We assessed this as very low‐quality evidence because of high risk of bias and small size. </p> </section> <section id="CD012637-sec-0105"> <h5 class="title">Other adverse events</h5> <p><a href="./references#CD012637-bbs2-0001" title="AxelssonB , BorupS . Is there an additive analgesic effect of paracetamol at step 3? A double‐blind randomized controlled study. Palliative Medicine2003;17(8):724‐5. [DOI: 10.1177/026921630301700816] ">Axelsson 2003</a> did not report on adverse events. <a href="./references#CD012637-bbs2-0002" title="CuberoDI , delGiglioA . Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double‐blind, placebo‐controlled study. Supportive Care in Cancer2010;18(2):235‐42. [DOI: 10.1007/s00520‐009‐0649‐8] ">Cubero 2010</a> reported no difference between groups for intensity of symptoms of constipation, xerostomia (dry mouth), nausea, vomiting, and somnolence. <a href="./references#CD012637-bbs2-0003" title="IsraelFJ , ParkerG , CharlesM , ReymondL . Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high‐dose strong opioids: a randomized, double‐blind, placebo‐controlled, crossover trial. Journal of Pain and Symptom Management2010;39(3):548‐54. [DOI: 10.1016/j.jpainsymman.2009.07.008] ">Israel 2010</a> found no difference between groups for intensity of nausea, drowsiness, unclear thinking, and constipation. </p> <p>We assessed this as very low‐quality evidence because of high risk of bias and small size. </p> </section> <section id="CD012637-sec-0106"> <h5 class="title">Withdrawal due to adverse events</h5> <p>None of the studies specifically reported on withdrawals due to adverse events.</p> <p>We assessed this as very low‐quality evidence because of high risk of bias and small size. </p> </section> <section id="CD012637-sec-0107"> <h5 class="title">Withdrawal due to lack of efficacy</h5> <p>Four participants in <a href="./references#CD012637-bbs2-0002" title="CuberoDI , delGiglioA . Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double‐blind, placebo‐controlled study. Supportive Care in Cancer2010;18(2):235‐42. [DOI: 10.1007/s00520‐009‐0649‐8] ">Cubero 2010</a> withdrew early due to intense pain following the switch from morphine to methadone, but there were no data for treatment arms with, and without paracetamol. One participant in <a href="./references#CD012637-bbs2-0003" title="IsraelFJ , ParkerG , CharlesM , ReymondL . Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high‐dose strong opioids: a randomized, double‐blind, placebo‐controlled, crossover trial. Journal of Pain and Symptom Management2010;39(3):548‐54. [DOI: 10.1016/j.jpainsymman.2009.07.008] ">Israel 2010</a> withdrew early because of 'unstable pain' while receiving paracetamol. </p> <p>We assessed this as very low‐quality evidence because of high risk of bias and small size. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012637-sec-0108" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012637-sec-0108"></div> <section id="CD012637-sec-0109"> <h3 class="title" id="CD012637-sec-0109">Summary of main results</h3> <p>Few studies met the criteria for inclusion, particularly the nature of the efficacy results presented. Thus, the results of the studies available for paracetamol for cancer pain are insufficient to allow any conclusions to be drawn about its efficacy or harm in treating cancer pain. The evidence is insufficient to support or refute its use. </p> <p>No studies were found for the use of paracetamol alone in mild or moderate cancer pain. No studies were found using paracetamol alone or in combination with an opioid in children. </p> <p>The three available studies examined the use of paracetamol plus an opioid versus the opioid alone in studies where average pain scores were indicative of mild to moderate pain, with scores of between 2/10 and 5/10 on a 0 to 10 VAS scale. These showed no obvious additional benefit of paracetamol in terms of pain relief, quality of life, or participant satisfaction or preference. However, the median doses of daily morphine used were 60 mg, 70 mg, and 225 mg, with some individuals taking up to several hundred mg daily or more. In the circumstance, it may be argued that any additional analgesic effect of oral paracetamol would be difficult to detect. </p> <p>Excluded studies were of short duration, not randomised, or type of pain was not cancer pain. We know of one study outside our scope that randomly compared non‐steroidal anti‐inflammatory drugs (NSAIDs), aspirin, and paracetamol, without placebo, in a cross‐over design for one week each, but in a small number (typically 15) of participants (<a href="./references#CD012637-bbs2-0108" title="VentafriddaV , DeConnoF , PaneraiAE , MarescaV , MonzaGC , RipamontiC . Non‐steroidal anti‐inflammatory drugs as the first step in cancer pain therapy: double‐blind, within‐patient study comparing nine drugs. Journal of International Medical Research1990;18(1):21‐9. [DOI: 10.1177/030006059001800104] ">Ventafridda 1990</a>). The paracetamol dose was apparently 1500 mg daily, and it demonstrated less pain relief at that dose than NSAIDs or aspirin at the doses used. </p> <p>Reviews of opioids for cancer pain have used a primary efficacy outcome of people with moderate or severe cancer pain reduced to mild pain or no pain within 14 days of starting treatment, and some have reported that as many as 96% can achieve this outcome where it is reported (<a href="./references#CD012637-bbs2-0057" title="HadleyG , DerryS , MooreRA , WiffenPJ . Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010270.pub2] ">Hadley 2013</a>; <a href="./references#CD012637-bbs2-0112" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a>). While this is a methodologically difficult outcome to evaluate in people with initial mild or moderate pain, it was one of the primary outcomes sought, but it was not reported in the three included studies. </p> <p>Reporting of harms provided no useful information, and could not be expected to do so given the small size of the studies, individually and together. </p> <p>Where there are small numbers of small studies, there is a situation where a positive bias in favour of a therapy might be found (<a href="./references#CD012637-bbs2-0034" title="DechartresA , TrinquartL , BoutronI , RavaudP . Influence of trial sample size on treatment effect estimates: meta‐epidemiological study. BMJ2013;346:f2304. [DOI: 10.1136/bmj.f2304] ">Dechartes 2013</a>; <a href="./references#CD012637-bbs2-0035" title="DechartresA , AltmanDG , TrinquartL , BoutronI , RavaudP . Association between analytic strategy and estimates of treatment outcomes in meta‐analyses. JAMA2014;312:623‐30. [DOI: 10.1001/jama.2014.8166] ">Dechartres 2014</a>; <a href="./references#CD012637-bbs2-0045" title="FanelliD , CostasR , IoannidisJP . Meta‐assessment of bias in science. Proceedings of the National Academy of Sciences of the United States of America2017; Vol. 114, issue 14:3714‐9. [DOI: 10.1073/pnas.1618569114] ">Fanelli 2017</a>; <a href="./references#CD012637-bbs2-0085" title="NguyenTL , CollinsGS , LamyA , DevereauxPJ , DaurèsJP , LandaisP , et al. Simple randomization did not protect against bias in smaller trials. Journal of Clinical Epidemiology2017;84:105‐13. [DOI: 10.1016/j.jclinepi.2017.02.010] ">Nguyen 2017</a>; <a href="./references#CD012637-bbs2-0088" title="NüeschE , TrelleS , ReichenbachS , RutjesAW , TschannenB , AltmanDG , et al. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJ2010;341:c3515. [DOI: 10.1136/bmj.c3515] ">Nüesch 2010</a>) even by the random play of chance (<a href="./references#CD012637-bbs2-0023" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [DOI: 10.1093/ije/dyn188] ">Brok 2009</a>; <a href="./references#CD012637-bbs2-0075" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>; <a href="./references#CD012637-bbs2-0102" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis ‐ a simulation study. PLOS One2011;6(10):e25491. [DOI: 10.1371/journal.pone.0025491] ">Thorlund 2011</a>), and overemphasising results of underpowered studies or analyses has been criticised (<a href="./references#CD012637-bbs2-0013" title="AlBalawiZ , McAlisterFA , ThorlundK , WongM , WetterslevJ . Random error in cardiovascular meta‐analyses: how common are false positive and false negative results?. Interational Journal of Cardiology2013;168(2):1102‐7. [DOI: 10.1016/j.ijcard.2012.11.048] ">AlBalawi 2013</a>; <a href="./references#CD012637-bbs2-0095" title="RobertsI , KerK , EdwardsP , BeecherD , MannoD , SydenhamE . The knowledge system underpinning healthcare is not fit for purpose and must change. BMJ2015;350:h2463. [DOI: 10.1136/bmj.h2463] ">Roberts 2015</a>; <a href="./references#CD012637-bbs2-0104" title="TurnerRM , BirdSM , HigginsJP . The impact of study size on meta‐analyses: examination of underpowered studies in Cochrane reviews. PLOS One2013;8(3):e59202. [DOI: 10.1371/journal.pone.0059202] ">Turner 2013</a>). Despite having only small studies in this review, no positive effect of paracetamol was evident. </p> <p>The lack of evidence of effect of paracetamol for cancer pain is similar to the situation with musculoskeletal (<a href="./references#CD012637-bbs2-0067" title="MachadoGC , MaherCG , FerreiraPH , PinheiroMB , LinCW , DayRO , et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta‐analysis of randomised placebo controlled trials. BMJ2015;350:h1225. [DOI: 10.1136/bmj.h1225] ">Machado 2015</a>; <a href="./references#CD012637-bbs2-0097" title="SaragiottoBT , MachadoGC , FerreiraML , PinheiroMB , Abdel ShaheedC , MaherCG . Paracetamol for low back pain. Cochrane Database of Systematic Reviews2016, Issue 6. [DOI: 10.1002/14651858.CD012230] ">Saragiotto 2016</a>), and neuropathic pain (<a href="./references#CD012637-bbs2-0112" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a>), as well as a number of other chronic pain conditions (<a href="./references#CD012637-bbs2-0083" title="MooreRA , MooreN . Paracetamol and pain: the kiloton problem. European Journal of Hospital Pharmacy2016;23(4):187‐8. [DOI: 10.1136/ejhpharm‐2016‐000952] ">Moore 2016</a>). </p> </section> <section id="CD012637-sec-0110"> <h3 class="title" id="CD012637-sec-0110">Overall completeness and applicability of evidence</h3> <p>This review highlights our lack of knowledge about the effectiveness of paracetamol for cancer pain. The WHO ladder recommends non‐opioid analgesics for mild to moderate pain in the first two steps of the WHO ladder (<a href="./references#CD012637-bbs2-0109" title="Anonymous . WHO analgesic ladder. www.who.int/cancer/palliative/painladder/en/ (accessed 10 April 2017). ">WHO 2017</a>), and paracetamol in many countries is the mainstay of the first two steps. </p> <p>No studies addressed the use of paracetamol alone (first step), and while the three included studies addressed paracetamol added to opioids, there was only low‐quality evidence for all outcomes. Only 122 participants were randomised in the three included studies, fewer than the 140 in an ongoing study that might be more instructive (<a href="./references#CD012637-bbs2-0012" title="University of Edinburgh. A double‐blind randomised parallel group trial of paracetamol versus placebo in conjunction with strong opioids for cancer related pain. clinicaltrials.gov/ct2/show/NCT02706769 (accessed 30 March 2017)2016. ">NCT02706769</a>), at least for the combination of paracetamol with strong opioids. </p> <p>None of the studies reported on any of the primary outcomes of efficacy, which are known to be important to people with pain (<a href="./references#CD012637-bbs2-0079" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013a</a>). None of the available evidence addresses other important outcomes, such as quality of life, reducing sweats, or improving sleep. </p> </section> <section id="CD012637-sec-0111"> <h3 class="title" id="CD012637-sec-0111">Quality of the evidence</h3> <p>Our GRADE judgement was very low quality for all outcomes. Very low quality means that this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different is very high. </p> <p>Studies were small in size and number. All were at high risk of bias for incomplete outcome data and size; no study was unequivocally at low risk of bias for all criteria. </p> </section> <section id="CD012637-sec-0112"> <h3 class="title" id="CD012637-sec-0112">Potential biases in the review process</h3> <p>We are unaware of any biases in the review process. A number of the authors prescribe or have prescribed paracetamol for cancer pain, or have been involved with its use in people with cancer pain. </p> </section> <section id="CD012637-sec-0113"> <h3 class="title" id="CD012637-sec-0113">Agreements and disagreements with other studies or reviews</h3> <p>Our findings are in broad agreement with a previous Cochrane review (<a href="./references#CD012637-bbs2-0116" title="McNicolED , StrasselsS , GoudasL , LauJ , CarrDB . NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD005180.pub2] ">McNicol 2015</a>) and other reviews in adults (<a href="./references#CD012637-bbs2-0072" title="MercadanteS , GiarratanoA . The long and winding road of nonsteroidal anti‐inflammatory drugs and paracetamol in cancer pain management: a critical review. Critical Reviews in Oncology/Hematology2013;87:140‐5. [DOI: 10.1016/j.critrevonc.2013.01.001] ">Mercadante 2013</a>; <a href="./references#CD012637-bbs2-0084" title="NabalM , LibradaS , RedondoMJ , PigniA , BrunelliC , CaraceniA . The role of paracetamol and nonsteroidal anti‐inflammatory drugs in addition to WHO Step III opioids in the control of pain in advanced cancer. A systematic review of the literature. Palliative Medicine2012;26(4):305‐12. [DOI: 10.1177/0269216311428528] ">Nabal 2012</a>), and children (<a href="./references#CD012637-bbs2-0073" title="MercadanteS , GiarratanoA . Pharmacological management of cancer pain in children. Clinical Reviews in Oncology and Hematology2014;91(1):93‐7. [DOI: 10.1016/j.critrevonc.2014.01.005] ">Mercadante 2014</a>). In this review, we included only studies with a minimum treatment period of five days, excluding some studies of short duration in these earlier reviews, but allowing any pain relieving effects of paracetamol that might be seen in clinical practice to emerge. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012637-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012637.pub2/media/CDSR/CD012637/urn:x-wiley:14651858:media:CD012637:CD012637-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012637.pub2/media/CDSR/CD012637/image_t/tCD012637-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012637-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012637.pub2/media/CDSR/CD012637/image_n/nCD012637-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012637.pub2/full#CD012637-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012637.pub2/media/CDSR/CD012637/image_n/nCD012637-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012637-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012637.pub2/media/CDSR/CD012637/urn:x-wiley:14651858:media:CD012637:CD012637-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012637.pub2/media/CDSR/CD012637/image_t/tCD012637-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012637-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012637.pub2/media/CDSR/CD012637/image_n/nCD012637-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012637.pub2/full#CD012637-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012637.pub2/media/CDSR/CD012637/image_n/nCD012637-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012637-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Paracetamol plus opioid compared with the same dose of opioid alone for cancer pain</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cancer pain </p> <p><b>Settings:</b> inpatient or outpatient </p> <p><b>Intervention:</b> paracetamol plus opioid </p> <p><b>Comparison:</b> same dose of opioid alone </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> opioid + paracetamol</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with<br/> opioid alone</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>RR<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of studies, participants</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with at least 30% or at least 50% reduction in pain</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality because no or inadequate data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PGIC much or very much improved</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality because no or inadequate data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean pain intensity at end of study</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No difference between treatment groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies, 93 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality because no or inadequate data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain no worse than mild at one or two weeks (or equivalent)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality because no or inadequate data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean quality of life or "well‐being"</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No difference between treatment groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies, 93 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality because no or inadequate data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant preference</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Better: 15/52</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Better: 9/52</p> <p>(No different: 28/52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies, 52 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality because no or inadequate data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No difference between groups for specific opioid‐related adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies, 80 participants (maximum)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality because no or inadequate data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>None specifically reported. 1 death due to underlying disease ‐ treatment unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies, 93 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low quality because no or inadequate data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Descriptors for levels of evidence (<a href="./references#CD012637-bbs2-0044" title="EffectivePractice , Organisation of Care(EPOC) . 23. Worksheets for preparing a Summary of Findings using GRADE. Resources for review authors. epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 30 November 2016). ">EPOC 2015</a>):<br/> <b>High quality:</b> This research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is low.<br/> <b>Moderate quality:</b> This research provides a good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is moderate.<br/> <b>Low quality:</b> This research provides some indication of the likely effect. However, the likelihood that it will be substantially different<sup>†</sup> is high.<br/> <b>Very low quality:</b> This research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is very high. </p> <p><sup>†</sup> Substantially different: a large enough difference that it might affect a decision. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012637.pub2/full#CD012637-tbl-0001">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012637.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012637-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012637-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012637-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012637-note-0006">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012637-note-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012637-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD012637-note-0003">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD012637-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD012637-note-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012637-note-0009">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012637-note-0014">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012637\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012637\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012637\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012637\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012637\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012637\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012637\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012637\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012637\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012637\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012637\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012637\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012637\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012637\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012637\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012637\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012637\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012637\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012637.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012637.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012637.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012637.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012637.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717076048"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012637.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717076052"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012637.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918daf178b36936e',t:'MTc0MDcxNzA3Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 